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Abstract
Endogenous opioids acting at μ-opioid receptors (MOPR) mediate many biological functions.
Pharmacological intervention at these receptors has greatly aided in the treatment of acute and chronic
pain, in addition to other uses. However, the development of tolerance and dependence has made it
difficult to adequately prescribe these therapeutics. A common single nucleotide polymorphism (SNP),
A118G, in the MOPR gene can affect opioid function and, consequently, has been suggested to contribute
to individual variability in pain management and drug addiction. Investigation into the role of A118G in
human disease and treatment response has generated a large number of association studies across
various disease states as well as physiological responses. However, characterizing the functional
consequences of this SNP and establishing if it causes or contributes to disease phenotypes have been
significant challenges. To clarify the functional mechanisms linking the OPRM1 A118G SNP to addiction
and analgesia phenotypes, we derived a mouse model possessing the equivalent nucleotide/amino acid
substitution in the mouse Oprm1 gene. I first evaluated MOPR expression and function using molecular
and pharmacological techniques and, subsequently, investigated how these alterations affected basal
and morphine-evoked responses using a variety of behavioral tasks. In order to better understand the
synaptic and circuit-level alterations conferred by this SNP, we employed voltage-sensitive dye imaging in
hippocampal slice preparations to evaluate basal and opioid-stimulated neuronal responses. Mice
harboring this SNP (A112G) demonstrated several phenotypic similarities to humans carrying the A118G
SNP, including reduced mRNA expression and morphine-mediated antinociception. We found additional
phenotypes associated with this SNP including significant reductions of receptor protein levels, morphinemediated hyperactivity, and locomotor sensitization, as well as sex-specific reductions in the rewarding
properties of morphine and the aversive components of naloxone-precipitated morphine withdrawal.
Functionally, this SNP reduced opioid-stimulated excitatory responses in the hippocampus. Together,
these findings extend our understanding of the functional consequences of this SNP and support
evidence suggesting that this SNP results in a loss of receptor function. Further cross-species analysis
will allow us to investigate mechanisms and adaptations present in humans carrying this SNP.
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ABSTRACT

FUNCTIONAL CHARACTERIZATION OF THE OPRM1 A118G SINGLE
NUCLEOTIDE POLYMORPHISM IN MICE
Stephen Daniel Mague
Supervisor: Dr. Julie Blendy

Endogenous opioids acting at µ-opioid receptors (MOPR) mediate many biological
functions. Pharmacological intervention at these receptors has greatly aided in the
treatment of acute and chronic pain, in addition to other uses. However, the development
of tolerance and dependence has made it difficult to adequately prescribe these
therapeutics. A common single nucleotide polymorphism (SNP), A118G, in the MOPR
gene can affect opioid function and, consequently, has been suggested to contribute to
individual variability in pain management and drug addiction. Investigation into the role
of A118G in human disease and treatment response has generated a large number of
association studies across various disease states as well as physiological responses.
However, characterizing the functional consequences of this SNP and establishing if it
causes or contributes to disease phenotypes have been significant challenges. To clarify
the functional mechanisms linking the OPRM1 A118G SNP to addiction and analgesia
phenotypes, we derived a mouse model possessing the equivalent nucleotide/amino acid
substitution in the mouse Oprm1 gene. I first evaluated MOPR expression and function
using molecular and pharmacological techniques and, subsequently, investigated how
these alterations affected basal and morphine-evoked responses using a variety of
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behavioral tasks. In order to better understand the synaptic and circuit-level alterations
conferred by this SNP, we employed voltage-sensitive dye imaging in hippocampal slice
preparations to evaluate basal and opioid-stimulated neuronal responses. Mice harboring
this SNP (A112G) demonstrated several phenotypic similarities to humans carrying the
A118G

SNP,

including

reduced

mRNA

expression

and

morphine-mediated

antinociception. We found additional phenotypes associated with this SNP including
significant reductions of receptor protein levels, morphine-mediated hyperactivity, and
locomotor sensitization, as well as sex-specific reductions in the rewarding properties of
morphine and the aversive components of naloxone-precipitated morphine withdrawal.
Functionally, this SNP reduced opioid-stimulated excitatory responses in the
hippocampus. Together, these findings extend our understanding of the functional
consequences of this SNP and support evidence suggesting that this SNP results in a loss
of receptor function. Further cross-species analysis will allow us to investigate
mechanisms and adaptations present in humans carrying this SNP.
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Abstract
Endogenous opioids acting at µ-opioid receptors mediate many biological
functions. Pharmacological intervention at these receptors has greatly aided in the
treatment of acute and chronic pain, in addition to other uses. However, the development
of tolerance and dependence has made it difficult to adequately prescribe these
therapeutics. A common single nucleotide polymorphism (SNP), A118G, in the µ-opioid
receptor gene can affect opioid function and, consequently, has been suggested to
contribute to individual variability in pain management and drug addiction. Investigation
into the role of A118G in human disease and treatment response has generated a large
number of association studies across various disease states as well as physiological
responses. However, characterizing the functional consequences of this SNP and
establishing if it causes or contributes to disease phenotypes have been significant
challenges. In this manuscript, we will review a number of association studies as well as
investigations of the functional impact of this gene variant. In addition, we will describe a
novel mouse model that was generated to recapitulate this SNP in mice. Evaluation of
models that incorporate known human genetic variants into a tractable system, like the
mouse, will facilitate the understanding of discrete contributions of SNPs to human
disease.

Keywords: alcohol; morphine; analgesia; dependence; pain; stress
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1. Introduction
The opioid system plays a role in diverse biological functions, including reward,
analgesia, and stress responsivity (Kreek and Koob, 1998; Vaccarino and Kastin, 2000).
Therapeutically, opioids are commonly prescribed for their effective analgesic properties.
However, the response to treatments varies widely between individuals leaving many
people taking the wrong dose, experiencing unbearable side effects, or receiving
inadequate therapy. Additionally, chronic use is marred by habituation, tolerance, and the
development of dependence, which occur in varying degrees depending on the individual.
The ability to better predict clinical outcomes based on individual differences to opioid
therapeutics would greatly reduce the trial and error of finding suitable drugs and doses,
and could reduce the number of patients developing drug dependence.
Individual variability results from a complex interaction of genetic and
environmental factors. However, linkage disequilibrium, genome-wide association, casecontrolled, and family-controlled studies have demonstrated the heritability of complex
behaviors and response to drug treatments, suggesting that specific genes or alterations in
genes may be responsible for the differences in behavior. Common genetic variations
among individuals include single nucleotide polymorphisms (SNPs), in which a single
nucleotide of the genome is altered. SNPs occur every 100-300 base pairs and account for
approximately 90% of human genetic variation. The nature of the change produced by the
SNP greatly depends on which nucleotide is being altered and where this change occurs
in the gene. For instance, synonymous SNPs will alter the nucleotide without changing
the resulting amino acid (also called a “silent mutation”). Non-synonymous SNPs are
4

produced when the nucleotide substitution alters the resulting amino acid. Additionally,
these alterations can occur in promotor, exonic, or intergenic regions and, consequently,
may differentially affect transcription, processing, stability, translation, folding,
transportation, and ultimately, function of the corresponding gene product.
In human populations, a commonly investigated SNP (rs1799971) occurs in exon
1 of the µ-opioid receptor gene (OPRM1), in which an adenine to guanine substitution
(A118G) exchanges an asparagine for an aspartic acid at a putative N-glycosylation site
(N40D). It is common in persons of European (15–30%) and Asian ancestry (40–50%),
with lower prevalence in African American and Hispanic populations (1-3%) (Bergen et
al., 1997; Gelernter et al., 1999; Tan et al., 2003). Despite the vast number of papers
investigating the role of this SNP in human disease and drug responses, a consensus has
yet to be reached on its functional consequences. The A118G SNP has been implicated in
a wide variety of disorders, such as drug addiction and stress responsivity, and in
treatment responses, including dependence and pain reduction; however, the mechanisms
that mediate these alterations have not been determined. In this manuscript, we will
review the relevant literature investigating the role of this SNP in human disease and
treatment response, molecular and cellular function, and animal models that may help
explain these effects. Indeed, several comprehensive reviews describe the role of
pharmacogenetics, including OPRM1 and other genes, in specific disease states and
treatment responses, such as alcoholism/addiction (LaForge et al., 2000; Dick and
Foroud, 2003; Enoch, 2003; Oslin et al., 2006; Anton et al., 2008; Haile et al., 2008) and
pain (Lotsch et al., 2004; Skorpen et al., 2008; Kosarac et al., 2009); therefore, in this
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review we focus on the elucidation of the functional significance of the A118G SNP in
disease states both in humans and animal models.

2. The µ-opioid receptor (MOPR)
2.1. MOPR form and function
Early investigation of the endogenous targets of opioid drugs identified three
main classes of opioid receptors: µ, !, and ". The cloning and characterization of the
opioid receptors have impacted our understanding of their gene and protein structures.
The MOPR is a member of the G-protein-coupled receptor (GPCR) family and interacts
with (Gi/Go) heterotrimeric G-proteins. Activation of the receptor and subsequent
dissociation of the G-proteins results in the opening of G-protein-gated inwardlyrectifying K+ (GIRK) channels, inhibition of voltage-gated Ca2+ channels, and reduction
of adenylyl cyclase-mediated cAMP production, all of which serve to decrease membrane
potential, neuronal excitability, and neurotransmitter release in addition to affecting
second-messenger systems and gene expression.
Receptor activation is achieved through binding of endogenous or exogenous
ligands. #-endorphin, the peptide encoded by proopiomelanocortin (POMC), has high
affinity and selectivity for the MOPR and is considered the endogenous MOPR ligand. In
addition, a separate class of peptides has been proposed as µ-selective: the endomorphins
(Zadina et al., 1997). The preproenkephalin gene encodes enkephalin, the endogenous
ligands for the ! receptor, which has modest affinity for the MOPR as well (Raynor et al.,
1994). A large number of opioids and non-opioid ligands exist for this receptor; however,
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those most commonly prescribed for their effective analgesic properties include
morphine, codeine and oxycodone.
2.2. Genetic Variation in Human OPRM1
The human MOPR gene, OPRM1, [chromosome 6q24-q25] spans over 200kb
with at least 9 exons and 19 different splice variants under the control of multiple
promoters (Shabalina et al., 2009). The initial receptor subtype, MOPR-1, spanning
approximately 80kb and containing 4 exons (http://genome.ucsc.edu), is abundantly
expressed and has been most intensely studied. Its haplotype structure includes three
large blocks with >100 polymorphisms reported (http://www.hapmap.org). In addition to
the exon 1 A118G, there is in vitro functional evidence for only a few of these other
polymorphisms. Two promoter polymorphisms, G–554A and A–1320G have been shown
to affect transcription: G–554A decreases MOPR transcription but is extremely rare
(MAF<0.001) and the A–1320G variant increases transcription, although the exact
transcription factor binding to the site is unknown (MAF= 0.21) (Bayerer et al., 2007). In
exon 3, G779A (R260H), G794A (R265H), and T802C (S268P) have been shown to
decrease receptor coupling and signaling (Koch et al., 2000; Befort et al., 2001; Wang et
al., 2001). Other OPRM1 polymorphisms that have been identified and associated with
pain or opioid dependence including a short tandem (CA)n repeat (Kranzler et al., 1998),
C17T (A6V), which is found primarily in African Americans(Hoehe et al., 2000), and
C440G (S147C), which is extremely rare in the general population (MAF< 0.006) (Glatt
et al., 2007). To date, none of these polymorphisms have in vitro evidence supporting a
functional consequence.
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3. A118G and drug dependence
Mesolimbic dopamine (DA) neurons in the ventral tegmental area (VTA) that
project to the nucleus accumbens (NAc) are part of a well-defined pathway involved in
reward processing (Nestler, 2005). GABAergic interneurons in the VTA maintain a tonic
inhibition over dopaminergic neurons. Binding of #-endorphin or morphine to MOPRs on
these interneurons will decrease their activity, resulting in disinhibition of the DA
neurons and elevations of DA in the NAc (Johnson and North, 1992). This dopamine
influx has been associated with reward and reinforcement and is believed to contribute to
the development of drug dependence (Wise and Bozarth, 1985; Di Chiara and Imperato,
1988).
A number of studies have examined OPRM1 as a candidate for genetic
contribution to the risk for substance dependence. The minor G118 allele has been
associated with an altered susceptibility for developing drug dependence, with some
studies suggesting that the SNP is a risk factor and others finding it to be protective, in
addition to several studies that did not report any significant contribution of the G118
allele (Table 1). For instance, in a sample of 476 Caucasians grouped according to drug
history – alcohol alone, alcohol and nicotine, or alcohol, nicotine, and illicit drug use and
compared to two control groups – it was found that individuals homozygous for the A118
allele were present in greater frequency in the drug groups compared to controls. The
absence of the G118 allele in the drug groups suggested it was protective against
developing drug dependence (Schinka et al., 2002). Alternatively, in drug-dependent
individuals in Eastern European and Russian populations, the G118 allele occurred more
frequently (Zhang et al., 2006a). In addition, several studies using linkage disequilibrium
8

or haplotype analysis (Crowley et al., 2003; Luo et al., 2003), case- or family-controlled
studies (Gelernter et al., 1999; Franke et al., 2001; Xuei et al., 2007), or meta-analyses of
past studies (Arias et al., 2006) failed to detect a significant involvement of A118G in
drug dependence.
3.1. Alcohol
Alcohol has been shown to affect a wide variety of transmitter systems; however,
the rewarding and reinforcing aspects of alcohol intake seem to be mediated by the opioid
system (Gianoulakis, 2004; Oswald and Wand, 2004). Indeed, acute alcohol
administration has been shown to cause #-endorphin release measured in the plasma
(Gianoulakis and Barcomb, 1987) or in reward-related brain regions (Rasmussen et al.,
1998). MOPRs appear critical for mediating alcohol effects as MOPR knock-out mice
show reduced ethanol intake and reward (Roberts et al., 2000; Hall et al., 2001).
Likewise, antagonism of the receptor by naloxone in rats (Reid et al., 1986) and
naltrexone in humans (O'Malley et al., 1992; Volpicelli et al., 1992) has been shown to
reduce alcohol intake.
Studies investigating alcohol-dependence specifically have reported positive
associations with the A118G SNP (Rommelspacher et al., 2001; Kim et al., 2004; Bart et
al., 2005; Nishizawa et al., 2006; Miranda et al., 2010), no association (Bergen et al.,
1997; Sander et al., 1998; Gscheidel et al., 2000; Kim et al., 2004; Loh el et al., 2004), or
a protective effect (Town et al., 1999) in individuals possessing the G118 allele (Table 1).
[For a detailed review of 12 of these clinical association studies, see (van der Zwaluw et
al., 2007).].
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A number of clinical studies have investigated altered effects of alcohol in
individuals with the G118 allele. For instance, in a sample of 38 moderate and heavy
drinkers without a history of alcohol problems or quit attempts, it was shown that G118
allele-carriers reported higher feelings of intoxication, stimulation, sedation, and
happiness compared to A118 allele-carriers. Subjects carrying the G118 allele were also
three times more likely to report a family history of alcohol use (Ray and Hutchison,
2004). In male heavy drinkers, G118 allele-carriers showed automatic approach
tendencies for alcohol and other appetitive stimuli, but not for generally positive or
negative stimuli (Wiers et al., 2009) and reported greater alcohol craving in a cuereactivity task (van den Wildenberg et al., 2007). A recent study investigating the
involvement of A118G in adolescent alcohol misuse found that a higher percentage of
G118 allele-carriers tested positive for an alcohol use disorder, and that the G118 allele
was associated with increased self-reports of drinking in order to enhance positive affect
(Miranda et al., 2010). Functionally, G118 allele-carriers have demonstrated an increased
BOLD response in fMRI in the orbitofrontal cortex, ventromedial prefrontal cortex, and
striatum in response to alcohol and alcohol-related cues (Filbey et al., 2008).
Additionally, a significant increase in dopamine receptor sensitivity, as measured by
increases in apomorphine-induced growth hormone secretion, was found in G118 allelecarrying alcoholics following one week of alcohol abstinence (Smolka et al., 1999).
One of the more therapeutically relevant findings regarding the A118G SNP is in
the treatment of alcoholism. It was discovered that individuals carrying the G118 allele
were more likely to respond positively to naltrexone treatment (Crowley et al., 2003). In
this study, there were 3.5 times more naltrexone-treated G118 allele-carriers, compared
10

with A118 allele-carriers, who did not relapse to heavy drinking. There were no
differences in rates of abstinence, suggesting that individuals with the G118 allele may
better handle alcohol exposure without fully relapsing to heavy drinking. There were no
differences between genotypes for those receiving placebo treatments, demonstrating that
the benefit of the G118 allele is specific for naltrexone treatment and does not confer an
enhanced ability for the individual to refrain from relapse. Subsequent studies
investigating the involvement of this SNP in naltrexone response have replicated these
initial findings (Oslin et al., 2003; Anton et al., 2008; Kim et al., 2009; Oroszi et al.,
2009). For instance, using a haplotype-based approach, the A118G locus, and not SNPs
found in the same haplotype block, contributed to the improved response to naltrexone
treatment in alcohol-dependent subjects with the G118 allele (Oroszi et al., 2009).
However, other studies failed to find an association between the G118 allele and an
improved response to naltrexone (Gelernter et al., 2007; Arias et al., 2008; Tidey et al.,
2008) or nalmefene treatment (Arias et al., 2008).
The mechanisms underlying the interaction of the A118G SNP and the potential
benefits of naltrexone in alcohol dependence are unknown. It is thought that the effect of
naltrexone is mediated by its ability to block the elevations in #-endorphin induced by
alcohol administration, which are thought to contribute to the subsequent euphoria.
Indeed, it has been shown that naltrexone has a greater propensity to block alcoholinduced highs in individuals with the G118 allele (Ray and Hutchison, 2007), which may,
in part, explain the reduction in rates of relapse. In contrast, it was shown that the urge to
drink following naltrexone treatment was greater in G118 allele-carriers (McGeary et al.,
2006). However, it should be noted that in this study, conducted in non-treatment seekers,
11

the urge to drink was evaluated following exposure to alcohol cues rather than alcohol
administration.
Cortisol responses have also been implicated in drinking behavior. A study in
non-treatment-seeking alcohol-dependent subjects found that G118 allele-carriers showed
a trend towards decreased cortisol responses to stress, but elevated alcohol craving and
intake following the stress (Pratt and Davidson, 2009). In animal models of addiction,
discrete brain substrates have been identified for drug-, cue-, and stress-mediated
reinstatement to drug-seeking behavior (Kalivas and McFarland, 2003). As such, it is
possible that this SNP may confer benefits in certain situations, but could serve as a
detriment (or not play a role) in others. [For additional information on alteration in stressrelated responses, see Chapter 1, section 4.2 “OPRM1 A118G and physiological
response: Stress”.]
3.2. Heroin
Heroin directly stimulates MOPRs when converted to morphine in the brain and
periphery. Similarly to alcohol, this results in activation of reward-related pathways,
initially resulting in euphoria, but eventually leading to abuse and dependence. Studies
evaluating the role of G118 allele in heroin dependence have reported positive
associations (Szeto et al., 2001; Bart et al., 2004; Drakenberg et al., 2006; Kapur et al.,
2007), negative associations (Bond et al., 1998; Tan et al., 2003), or no association (Shi
et al., 2002; Glatt et al., 2007) (Table 1). For instance, one study found that
approximately 90% of G118 allele-carriers were heroin users. Additionally, they found
that preproenkephalin and preprodynorphin levels, which were reduced in heroindependent subjects, were even lower in G118 allele-carriers compared with A118 allele12

carriers (Drakenberg et al., 2006). Shi and colleagues found that the G118 allele was
associated with elevated daily intake of heroin in dependent subjects, though they did not
find a significant effect of genotype and heroin dependence (Shi et al., 2002). A positive
response to initial drug exposure is typically associated with continued use and abuse. In
a study investigating the relationship between initial drug response and OPRM1 SNPs,
the G118 allele was not associated with positive or negative subjective responses to firsttime heroin use (Zhang et al., 2007), suggesting that differences in rates of dependence
may not be explained by differences in initial euphoric experience.
3.3. Nicotine
The rewarding properties of nicotine are, in part, mediated by opioid transmission.
For instance, it has been shown that nicotine stimulates the release of endogenous opioids
in reward-related brain regions (Davenport et al., 1990; Pomerleau, 1998), blockade of
MOPRs with systemic injections of naloxone blocks acute nicotine reward (Walters et al.,
2005), MOPR null mutant mice do not show nicotine reward (Berrendero et al., 2002),
and repeated treatment with nicotine elevates MOPR mRNA in the VTA (Walters et al.,
2005). Human studies have reported an association of chromosome 6, which contains
OPRM1, with nicotine dependence (Sullivan et al., 2004; Vink et al., 2004) (Table 1).
Another study, however, found that the A118G SNP was not significantly associated with
nicotine dependence, though it was in high linkage disequilibrium with haplotypes that
did reach significance, suggesting there may be other SNPs nearby that confer an
increased susceptibility for developing nicotine dependence (Zhang et al., 2006b). As in
the case with alcohol, studies examining differences in response to nicotine
administration have revealed some interesting associations. For instance, female G118
13

allele-carriers report attenuated rewarding effects of nicotine (Ray et al., 2006). In a
separate study, nicotine was administered following the induction of a positive or
negative mood via pictures and music. Smoking was reported as more rewarding to A118
allele-carriers when in a negative mood than it was for those with the G118 allele,
suggesting that the A118 allele-carriers may respond more to the mood-enhancing
properties of nicotine (Perkins et al., 2008). Accordingly, increases in cerebral blood flow
to brain regions associated with cigarette craving were detected in smokers with the A118
allele compared to the G118 allele (Wang et al., 2008).
Consistent with alcohol studies, the A118G SNP may better predict treatment
outcomes and relapse rates for those attempting to quit smoking rather than predict the
susceptibility for developing nicotine dependence. Lerman and colleagues have shown
that smokers with the G118 allele are significantly less likely to relapse and report fewer
abstinence symptoms than smokers homozygous for the A118 allele (Lerman et al.,
2004). A group in the UK reported that female G118 allele-carriers had significantly
higher quit rates than female A118 allele-carriers; while the reverse was true for males
(Munafo et al., 2007). It should be noted, however, that this study obtained DNA from
only 50% of subjects, raising the possibility of ascertainment bias. This evidence
supporting the role of the G118 allele in dependence phenotypes, such as liking and
craving in chronic smokers, is more robust than evidence for association with the
development of nicotine dependence.
3.4. Methamphetamine
The effects of methamphetamine (MA), which are predominantly mediated by
dopaminergic and serotonergic systems, may also involve the endogenous opioid
14

systems. Indeed, work in animals has shown that naloxone administration can block
behavioral sensitization to repeated MA exposure (Chiu et al., 2005). However, the few
studies investigating the effect of the A118G SNP in MA dependence failed to find an
association (Ide et al., 2004; Ide et al., 2006) (Table 1).

4. A118G and physiological response
4.1. Pain and analgesia
The relationship between altered pain thresholds and analgesic responses to
opioid administration for the A118G SNP has been well characterized. In a variety of
populations, the G118 allele has been associated with elevated pain responses and
decreased pain thresholds (Sia et al., 2008; Tan et al., 2009) and a reduced response to
morphine or other opioids for patients receiving treatment for post-operative or chronic
pain (Klepstad et al., 2004; Fillingim et al., 2005; Chou et al., 2006a; Chou et al., 2006b;
Coulbault et al., 2006; Janicki et al., 2006; Oertel et al., 2006; Reyes-Gibby et al., 2007;
Campa et al., 2008; Hayashida et al., 2008; Landau et al., 2008; Sia et al., 2008; Tan et
al., 2009) (Table 2). Additionally, in healthy volunteers carrying the G118 allele, higher
concentrations of alfentanil, an opioid analgesic, were required for pain relief following
electrical pain stimulation (Oertel et al., 2006); of interest, this dose did not increase
respiratory depression, suggesting it may be safe to give a higher dose of opioid
analgesics to patients that carry the G118 allele. Other studies, however, have reported
divergent results, showing that G118 was associated with reduced pain responses. For
instance, in healthy volunteers receiving different experimental pain procedures, the
G118 allele was associated with reduced pain responses to pressure (Fillingim et al.,
15

2005). Additionally, males carrying the G118 allele rated thermal pain lower than those
carrying the A118 allele. However, the G118 allele-carrying females reported higher pain
scores following this thermal pain administration, consistent with previous literature
demonstrating elevated pain responses (Fillingim et al., 2005).
Morphine-6#-glucuronide (M6G) is an active metabolite of morphine that has a
greater analgesic potency but a reduced potency in affecting respiratory depression
(Mantione et al., 2005). In G118 allele-carrying subjects, there was a reduced potency of
M6G in eliciting an analgesic response, though there was no difference in M6G-induced
respiratory depression (Romberg et al., 2005). A reduction in M6G-induced miosis was
also found in G118 allele-carriers (Lotsch et al., 2002).
MOPRs also play a role in social pain, described as the feelings that result from
social rejection, separation, or loss. Accordingly, the G118 allele was associated with
increased self-reported sensitivity to rejection (Way et al., 2009). Subsequent fMRI
measurement of neural responses in these individuals found greater activation in the
dorsal anterior cingulate cortex and anterior insula while experiencing social rejection,
suggesting a decrease in MOPR inhibitory modulation in G118 allele-carriers. These
brain regions are associated with both physical and social pain (Eisenberger and
Lieberman, 2004). Together, these data support a loss of function of the MOPR in
individuals harboring the G118 allele in some, but not all, responses mediated by the
same compounds.
4.2. Stress response
Activation of the hypothalamic-pituitary-adrenal (HPA) axis plays an integral role
in responses to stress. Following a stressor, corticotropin-releasing factor (CRF) is
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released from the paraventricular nucleus (PVN) of the hypothalamus, stimulating POMC
synthesis in the pituitary and the release of two POMC metabolites: adrenocorticotropic
hormone (ACTH) and #-endorphin. Acting on the adrenal glands, ACTH stimulates the
release of glucocorticoids (cortisol in primates and corticosterone in rodents; CORT),
which can then have many central and peripheral effects. MOPRs located on CRF
neurons in the PVN serve to tonically inhibit HPA axis stimulation; thus, differences in
endogenous opioid transmission or receptor activity can alter basal CORT levels or
stress-mediated CORT responses. Just as genetic differences can affect response to drugs
(pharmacogenetics), alterations in responses to an individual’s own biologically active
compounds (physiogenetics) are influenced by genetic differences (Kreek and LaForge,
2007). Indeed, individuals with the G118 allele have baseline elevations in CORT levels
(Hernandez-Avila et al., 2003; Bart et al., 2006). Several studies have shown that the
CORT-response to a behavioral stressor is lower in G118 allele-carriers (Chong et al.,
2006; Pratt and Davidson, 2009).
In contrast, a greater CORT response has been observed in G118 allele-carriers
following a naloxone challenge, which may suggest an elevated tonic inhibition of CRF
by #-endorphin (Hernandez-Avila et al., 2003; Chong et al., 2006; Hernandez-Avila et
al., 2007). Interestingly, one of these studies found population-specific effects in which
G118 allele-carriers of European descent displayed elevations in CORT responses to
naloxone, while G118 allele-carriers of East Asian descent did not (Hernandez-Avila et
al., 2007). These population-specific differences could suggest that the A118G SNP is in
high linkage disequilibrium (LD) with other SNPs that may mediate the observed
alterations.
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5. Functional relevance of A118G
Most studies to date have examined the functional consequences of this SNP in
vitro using various cell culture systems. Initial studies identified an elevated binding
affinity of #-endorphin, but not exogenous ligands, in the G118 variant to 3-fold higher
than that of the A118 in AV-12 cells stably expressing the human MOPR (hMOPR)
variants (Bond et al., 1998). Additionally, #-endorphin was found to be three times more
potent in activating GIRK channels in Xenopus oocytes injected with in vitro transcribed
mRNAs for the A118 or G118 variants (Bond et al., 1998). Together, these data
suggested a gain-of-function of the MOPR as a consequence of the A118G point
mutation. However, subsequent studies using other cell culture systems – COS cells
(Simian fibroblasts) (Befort et al., 2001) or HEK 293 cells (Human embryonic kidney)
(Beyer et al., 2004) – were less conclusive with regard to this altered function of the
G118 allele. Another consequence of MOPR activation, Ca2+ inhibition, was investigated
using rat sympathetic superior ganglion (SCG) neurons expressing either the A118 or
G118 variant of the hMOPR. In these studies, the potencies of both DAMGO- and
morphine-mediated Ca2+ current inhibition (but not morphine-6-glucuronide or
endomorphin I) were increased in SCG neurons expressing the G118 variant (Margas et
al., 2007), again suggesting enhanced response for some but not all opioid compounds.
A human post-mortem study examined allele-specific mRNA expression from
heterozygous individuals with the A118G polymorphism and found significant reductions
in mRNA transcribed from the G118 allele. Additionally, the authors transiently
expressed both variants of the MOPR in CHO cells and showed a reduction in mRNA
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and protein expression with the G118 allele (Zhang et al., 2005). The mechanisms
underlying the decrease in expression is unclear. As the mutation occurs in a coding
region, rather than a promotor, it might seem unlikely that transcription would be
affected. However, using in silico tools (bioinformatics), it has been proposed that the
A118G SNP may inactivate three transcription factor binding sites while creating two
new ones, including a p53 site (Pang et al., 2009), suggesting that cis-acting factors could
explain the alterations in expression. While transcriptional regulation using exonic
sequence is rare, some examples do exist. Using Mfold technology, in which theoretical
mRNA folding can be evaluated for different sequences, it was shown that the G118
variant demonstrated altered folding compared to other permutations which could affect
mRNA stability (Zhang et al., 2005; Johnson et al., 2008).
Further evidence for a decrease in MOPR expression was demonstrated by studies
showing a reduction in Bmax, indicative of a lower receptor number, following [3H]DAMGO binding using both transient and stable expression of MOPR in AV-12 and
HEK293 cells (Kroslak et al., 2007). Additionally, there was a decrease in agonistmediated cAMP signaling for morphine, methadone, and DAMGO, but not #-endorphin,
using stable expression in the two lines; this alteration in cAMP signaling was not seen in
cell lines transiently expressing the receptor (Kroslak et al., 2007). Another study using
HEK293 cells stably expressing the hMOPR also found a decrease in Bmax using
DAMGO binding in the G118 variant, though they did not find alterations in binding
affinity or signal transduction (Beyer et al., 2004). Conversely, a recent study
investigating MOPR expression, binding, and signaling in post mortem human tissue
from G118 allele-carriers found decreased agonist-induced receptor signaling efficacy in
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tissue from secondary somatosensory cortex, but not thalamus. However, there were no
alterations in receptor expression or binding affinity (Oertel et al., 2009). Together,
studies demonstrating that the G118 variant results in significantly reduced levels of
MOPR expression and/or signaling suggest a loss-of-function of the mutation, while
others reporting an increase in affinity and signaling suggest a gain-of-function.

6. Species-specific SNPs in OPRM1: Spontaneous and generated
6.1. Monkey orthologue (C77G)
Non-human primate research has been invaluable in the study of human disease
and behavior. A conserved SNP, in which a cystine is replaced by a guanine at position
77 (C77G) resulting in a substitution of arginine with proline (R26P), occurs in the Nterminal arm of the monkey orthologue OPRM1 and has been suggested to be
comparable to the A118G SNP (Miller et al., 2004). In this initial characterization of 32
male and female macaques, 44% were homozygous for the C77-allele, 50%
heterozygous, and 6% homozygous for the G77 allele. It was demonstrated that monkeys
possessing the minor allele (G77), had lower CORT levels both at baseline and following
dexamethasone suppression and subsequent ACTH challenge. In addition to lower CORT
levels, the G77 allele was associated with an increase in aggression threat, which is the
early communicative aspect of aggression occurring prior to actual physical actions. By
expressing these receptor-coding regions in HEK-293, the authors were able to identify
an elevated affinity of the G77 allele for #-endorphin (~3.5 fold), but not exogenous
ligands, similarly to original in vitro work in the A118G SNP (Bond et al., 1998).
Subsequent studies have shown an increase in attachment behavior in G77 allele-carrying
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infants, who displayed increased distress vocalization during protracted periods of
mother-infant separation and increased maternal contact during mother-infant reunion
(Barr et al., 2008), possibly reflecting increased attachment reward through enhanced #endorphin function. However, in light of the recent reports of increased social pain
associated with the G118 allele (Way et al., 2009), an alternate explanation could be that
the infants carrying the G118 allele had a greater sensitivity to maternal rejection,
possibly through reduced MOPR function in the neocortex.
A haplotype containing the C77G SNP was shown to result in an increase in
MOPR mRNA expression (Vallender et al., 2008). Though the human A118G SNP has
been shown to reduce mRNA expression rather than increase it, this serves as further
evidence that coding region SNPs may alter mRNA production, folding, or stability.
Interestingly, in studying alcohol consumption in these macaques, a sex $ genotype
interaction was found, in which male carriers of the G77 allele showed elevated ethanol
preference and consumption (Barr et al., 2007). In a subsequent study, macaques carrying
the G77 allele showed both enhanced alcohol preferences following vehicle
administration and greater reductions of alcohol preference following naltrexone
administration (Barr et al., 2010).
6.2. Knock-in mouse model (A112G)
Despite information gained from human post mortem tissues, a full understanding
of the OPRM1 A118G polymorphism requires extensive biochemical characterization
aligned with behavioral analysis, which is not feasible in human subjects. The mouse is a
tractable model system to study behavioral effects of this SNP while at the same time
allowing for detailed molecular and biochemical analysis in vivo. Homologous
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recombination technology can now be used to generate point mutations in mice for those
genes in which human SNPs have been identified. This approach, however, has not been
fully utilized due in part to the labor-intensive procedures involved in building the
complex targeting vectors required. Recent advances and the availability of bacterial
artificial chromosome (BAC) vectors have streamlined this process, making the use of
knock-in mice a natural progression to investigate human disease. To gain insight into the
role of the A118G variant in humans, we have generated the equivalent point mutation in
mice, A112G, which alters the same amino acid coding from an asparagine to aspartic
acid at position 38 (Asn38Asp; N38D), eliminating an N-linked glycosylation site.
A number of molecular, biochemical, and behavioral alterations that resemble
those previously identified in human and in vitro studies have been identified in G112
mice (Mague et al., 2009). For instance, the presence of the G112 allele results in
decreased MOPR mRNA and protein expression. This decrease in receptor expression
was also seen using [3H]-DAMGO binding, though there were no alterations in affinity
for #-endorphin or exogenous ligands (morphine, DAMGO, or naloxone). Mice with the
G112 allele showed only a modest elevation in locomotor activity following acute
morphine administration and failed to develop sensitization to repeated, intermittent
injections. Similarly, G112 mice had reduced morphine-induced antinociceptive
responses, though they showed similar signs of tolerance following repeated treatments.
A sex $ genotype interaction was found in measures of hedonia: female G112-carriers
did not display a preference for morphine-associated environments nor did they
demonstrate an aversion to environments associated with naloxone-precipitated
withdrawal.
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Since the A112G SNP alters MOPR expression, some of the behavioral outcomes
could be explained by the reduction in protein levels. Indeed, studies investigating opioid
responses in MOPR knockout heterozygous mice have found similar reductions in
morphine-mediated antinociception using tail flick and hot plate tests (Sora et al., 1997)
and sex-specific decreases in alcohol reward using voluntary ethanol consumption and
place-conditioning paradigms (Hall et al., 2001). However, these sex-specific differences
in ethanol reward were due in large part to elevated responses in wild type female mice
compared to wild type male mice, with little differences reported between male and
female heterozygous mice. Indeed in wild type male mice, no ethanol preference was
observed; therefore, it is difficult to assess whether or not heterozygous MOPR knockout
males displayed ethanol reward deficits. In addition to reducing expression levels, it
should be emphasized that one consequence of the A112G knock-in mouse (and the
A118G SNP) is the deletion of an N-linked glycosylation site. Glycosylation plays a role
in receptor sorting, expression, trafficking, ligand binding, and signal transduction (Fan et
al., 1997; Zhang et al., 2001; Rathz et al., 2002); alterations in these processes could
affect MOPR function in ways distinct from protein level changes.
The A112G mouse model, similarly to the C77G non-human primate model,
possesses analogous phenotypes as those reported in human studies and identifies new
behaviors that have not been investigated. The A112G mouse model seems to replicate
the loss-of-function phenotypes (e.g., decreased expression, reduced morphine-mediated
antinociception, decreased hedonic reward), though it should be noted that decreases are
not present in all morphine-mediated behaviors, suggesting that the alterations are
dependent on other factors, including brain region, other neurotransmitter systems, and
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sex. Future work will investigate the effects of the A112G SNP on alcohol consumption
and stress responsivity to evaluate whether or not these animals display any gain-offunction phenotypes as suggested by human studies.

7. Conclusion
The A118G SNP in the human OPRM1 gene has been studied intensely and
implicated in a variety of disease states and treatment responses. In particular, alterations
in receptor function resulting from this SNP are believed to contribute to the
susceptibility for developing drug dependence. The strongest evidence for a beneficial
effect of the A118G polymorphism stems from studies evaluating the response to
naltrexone for alcohol and nicotine consumption, highlighting the importance of
pharmacogenetics when devising treatment options to determine who may be more likely
to benefit from a given therapy. In addition to choosing treatment options, understanding
the mechanisms underlying these beneficial effects may allow us to develop therapies for
individuals with the common A118 allele.
As acute overdose and long-term dependence are concerns when treating acute
and chronic pain with opiates, it is important to minimize the dose prescribed in order to
reduce the amount of drug the patient receives. The evidence showing a diminished
response to opioid-mediated analgesia in G118 subjects illustrates the need for utilizing
pharmacogenetics when developing treatment options. For instance, though G118
patients require higher doses of opioids for pain management, it has also been shown that
they may be more resistant to the respiratory depressive effects of alfentanil than A118
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allele-carrying individuals, suggesting that there may be less risk in providing these
higher doses (Oertel et al., 2006).
Cross-species experiments allow investigators to validate both pharmacogenetic
and physiogenetic phenotypes. Despite the potential of this approach to yield valuable
information for treatment development, few mouse/human comparisons of SNPs have
been reported. The derivation of the Oprm1 A112G mouse will allow for such studies to
investigate aspects of this SNP that have yet to be delineated in human populations. We
know from human studies that the OPRM1 A118G SNP can impact the response to
treatment; however, we have learned from studies in mice that this SNP also influences
sex-specific drug behaviors, differences that have been largely ignored in human
association studies. Moreover, we anticipate that this mouse model may assist in drug
design to generate effective analgesics and other opioid therapies without the risk of
abuse liability.
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Table 1. Association studies investigating OPRM1 A118G involvement in drug
dependence in humans

Direction of
effect
Protective

Drug

Method

Finding

Substance
dependence

Association

Risk

Substance
dependence

Haplotype
analysis

Greater frequency
of A118 in drug
groups
Greater frequency
of haplotype
containing G118 in
drug-dependent
individuals

No
association
No
association

Substance
dependence
Substance
dependence

No
association

Substance
dependence

Case-controlled
association
Case- and
family-controlled
association
Family-based
association

No
association

Substance
dependence

Haplotype
analysis

No
association

Substance
dependence

Linkage
disequilibrium

No
association

Substance
dependence

Meta-analysis

Risk

Alcohol

Case-controlled
association

G118 associated
with alcohol
dependence

Risk

Alcohol

Case-controlled
association

Risk

Alcohol

Association

G118 associated
with alcohol
dependence
G118 associated
with more days
drinking per
month, but no
significant increase
in alcoholdependence
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Population (number
of subjects)
European American
(476)

Reference

Eastern European and
Russian (720)

(Zhang et al.,
2006a)

European American
(891)
German Caucasian

(Gelernter et al.,
1999)
(Franke et al.,
2001)

European American
(1923, from 219
multiplex alcohol
dependent families)
European American
and African American
(213 opioid
dependence and 196
“supercontrols”)
European-American
and African American
(442 substance
dependence and 234
control)
Caucasian (German,
Finnish, Swedish,
EA), AfricanAmerican, Asian,
Hispanic, NativeAmerican (8000)
Swedish (467
alcohol-dependent
and 170 healthy
volunteers)
Japanese (64 alcohol
dependent and 74
control)
Korean (112 alcohol
dependent and 140
control)

(Xuei et al., 2007)

(Schinka et al.,
2002)

(Crowley et al.,
2003)

(Luo et al., 2003)

(Arias et al.,
2006)

(Bart et al., 2005)

(Nishizawa et al.,
2006)
(Kim et al., 2004)

Table 1 continued.
Direction of
effect
Risk

Drug

Method

Finding

Alcohol

Association

Risk

Alcohol

Association

Protective

Alcohol

Association

Trend towards
increase of G118
in alcoholdependent subjects
G118 associated
with increased
alcohol use
disorder (AUD)
diagnoses in
adolescents
A118 associated
with risk for
alcoholism

Protective

Alcohol

Association

No
association

Alcohol

Case-controlled
association

No
association

Alcohol

Association

No
association

Alcohol

Association

No
association

Alcohol

Association

Risk

Heroin

Association

Risk

Heroin

Association

Risk

Heroin

Association

Risk

Heroin

Association

Protective

Heroin

Association

A118 had two-fold
greater risk for
alcohol
dependence

G118 associated
with heroin
dependence
90% of G118 were
heroin users
2.5-fold higher
frequency of G118
in opioid
dependent subjects
G118 associated
with heroin
dependence
A118 associated
with heroin in
Indian, but not
East Asian
populations
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Population (number
of subjects)
German (327 alcoholdependent, 340
control)

Reference

Mostly Caucasian (27
AUD and 160
control)

(Miranda et al.,
2010)

Mexican Americans
(365 alcoholdependent and 338
control)
Caucasian (105
alcohol-dependent
and 122 control)

(Du and Wan et
al., 2009)

German (327 alcohol
dependent; and 340
control)
US-Caucasian,
Finnish-Caucasian,
Souithwestern
American-Indian
(791)
German (327 alcoholdependent and 340
control)
Tawainese (158
alcohol-dependent,
149 control)
Swedish (139 heroindependent and 170
control)
European Caucasian
(118)
Indian (126 opioid
dependent and 156
control)

(Sander et al.,
1998)

Chinese men (200
heroin dependent and
97 control)
Indian (20 dependent,
117 control)
Malaysian (25
dependent, 131
control)
Chinese (52
dependent, 156
control)

(Szeto et al.,
2001)

(Rommelspacher
et al., 2001)

(Town et al.,
1999)

(Bergen et al.,
1997)

(Gscheidel et al.,
2000)
(Loh et al., 2004)
(Bart et al., 2004)
(Drakenberg et
al., 2006)
(Kapur et al.,
2007)

(Tan et al., 2003)

Table 1 continued.
Direction of
effect
Protective

Drug

Method

Finding

Heroin

Association

A118 associated
with heroin
dependence in
Hispanic subjects

No
association

Heroin

Association

No
association

Heroin

Family-based
association

Risk

Nicotine

Linkage
disequilibrium

Risk

Nicotine

Linkage analysis

No
association

Nicotine

Haplotype
analysis

QTLs on
chromosome 6
associated with
nicotine
dependence
Chromosome 6
associated with
nicotine
dependence
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Population (number
of subjects)
African-American (46
dependent, 16
controls)
Caucasian (60
dependent, 44
control)
Hispanic (116
dependent, 78
control)
Chinese (48 heroindependent, 48
control)
Chinese (1208 from
473 families with at
least two siblings
with opioid
dependence)
Dutch twins (536 DZ
from 192 families)

Reference

Caucasians from New
Zealand (sibling pairs
from 129 families
with nicotine
dependence)
Caucasians twins of
European ancestry
(688)

(Sullivan et al.,
2004)

(Bond et al.,
1998)

(Shi et al., 2002)
(Glatt et al.,
2007)

(Vink et al.,
2004)

(Zhang et al.,
2006)

Table 2. Association studies investigating OPRM1 A118G in pain experience and
opioid-mediated analgesia.
Drug

Method

Finding

Morphine

Pain Score and
morphine
consumption

Chronic
morphine

Pain Score and
morphine
consumption
Morphine
consumption

Reported pain and
morphine consumption
lowest in AA and highest
in GG
GG required more
morphine; no difference in
reported pain
GG required more
morphine to control pain

Chronic
morphine
Morphine

Morphine
consumption

Morphine

Morphine
consumption

Morphine

NRS and PPI

Morphine

Morphine
consumption

Morphine or
fentanyl

Opioid
consumption

Alfentanil

Electrical pain
stimulation

Opioid
(Oxycodone,
morphine,
methadone,
fentanyl patch,
intrathecal
pump)
No drug

Pain score (NRS)
and evaluation of
chronic pain
presence x
genotype
interaction

Morphine

Pain score and
morphine
consumption

Three experimental
pain procedures:
pressure, thermal,
and ischemic

GG consumed more
morphine that AA and AG;
no difference in reported
pain
G118 required more
morphine 24 hours
following surgery, but not
at 48; no differences in
reported pain
G118 were poor
responders to morphine
treatment
Trend towards an increase
in morphine consumption
in G118
GG required more opioid
at 24-hr post operation
compared to AA and AG
GG required higher opioid
concentration for pain
relief; respiratory
depression was not
increased with the elevated
dose
G118 was less common in
members of the chronic
pain group; more A118
members were resistant to
high-dose opioids.
G118 had higher pressurepain thresholds. Lower
thermal pain in G118-allele
men, higher in G118-allele
women.
G118 allele associated with
increased pain, increased
morphine consumption, but
reduced nausea
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Population (number of
subjects)
Singapore and Han Chinese
women receiving morphine
for post-cesarean pain
(588)
Norwegian Caucasians
receiving morphine for
cancer pain treatment (207)
Norwegian Caucasians
receiving morphine
treatment for cancer pain
(99)
Taiwanese patients
receiving morphine
following arthroplastic
knee surgery (147)
Taiwanese female patients
receiving morphine
following total abdominal
hysterectomy (80)

Reference

Italian Caucasian patients
receiving morphine
treatment for cancer pain
(145)
Mostly Caucasian
colorectal surgical patients
(74)
Japanese patients receiving
opioid treatment for open
abdominal surgery pain
(138)
Healthy German volunteers
(20)

(Campa et al.,
2008)

Mostly Caucasian patients
receiving opioid treatment
for elecetive laproscopic
abdominal surgery (101)

(Janicki et al.,
2006)

Healthy volunteers (mostly
Caucasian) (167)

(Fillingim et
al., 2005)

Women of varying Asian
ethnicities receiving
voluntary cesarian section
(994)

(Tan et al.,
2009)

(Sia et al.,
2008)
(Reyes-Gibby
et al., 2007)
(Klepstad et al.,
2004)
(Chou et al,,
2006b)
(Chou et al.,
2006a)

(Coulbault et
al., 2006)
(Hayashida et
al., 2008)
(Oertel et al.,
2006)

Dissertation Goals and Hypotheses
As detailed in this introductory chapter, the OPRM1 A118G SNP has been
implicated in a variety of disease states and treatment responses. However, the extent to
which this SNP alters these traits and the mechanisms that may underlie these alterations
have not been elucidated. In order to better understand the functional consequences of
this SNP, we generated mice possessing an equivalent Oprm1 polymorphism by
introducing a point mutation that eliminated an N-linked glycosylation site in exon 1. We
then utilized molecular, cellular, electrophysiological, and behavioral techniques to
investigate the alterations in receptor expression and function that result from this SNP.
Clinical and in vitro studies have reported evidence supporting both gains and
losses of function. By studying receptor expression and function in this mouse line, I
hoped to clarify these discrepancies and determine the mechanisms by which receptor
changes affect behavioral responses. Chapter 2 describes my initial evaluation of changes
in MOPR expression and function in mice possessing the Oprm1 SNP and the subsequent
investigation of how these alterations affect basal and morphine-evoked responses. Based
on the clinical and in vitro reports, we expected to find reductions in receptor expression
and function.
I further explored receptor alterations conferred by this SNP in Chapter 3.
Specifically, I employed voltage-sensitive dye imaging in hippocampus slice preparations
to evaluate how this SNP might affect circuit function. Since we had previously shown
decreases in receptor expression and reductions in morphine-mediated responses, we
expected to find decreased MOPR-stimulated circuit alterations in mice harboring the
Oprm1 SNP.
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These studies, together with clinical and in vitro findings from other labs, validate
this mouse model of the A118G SNP and extend our understanding of the functional
consequences of this SNP.
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Stephen D. Maguea, Carolina Isiegasa, Peng Huangd, Lee-Yuan Liu-Chend, Caryn
Lermanb,c, Julie A. Blendya,c,
Department of Pharmacologya, Psychiatryb, and Abramson Cancer Centerc, University of
Pennsylvania School of Medicine, Philadelphia, PA 19104
Department of Pharmacology and Center for Substance Abuse Researchd, Temple
University School of Medicine, Philadelphia, PA 19140
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ABSTRACT
A single nucleotide polymorphism (SNP) in the human µ-opioid receptor gene
(OPRM1 A118G) has been widely studied for its association in a variety of drug
addiction and pain sensitivity phenotypes; however, the extent of these adaptations and
the mechanisms underlying these associations remain elusive. To clarify the functional
mechanisms linking the OPRM1 A118G SNP to addiction and analgesia phenotypes, we
derived a mouse model possessing the equivalent nucleotide/amino acid substitution in
the Oprm1 gene. Mice harboring this SNP (A112G) demonstrated several phenotypic
similarities to humans carrying the A118G SNP, including reduced mRNA expression
and morphine-mediated antinociception. We found additional phenotypes associated with
this SNP including significant reductions of receptor protein levels, morphine-mediated
hyperactivity, and the development of locomotor sensitization in mice harboring the
G112 allele. In addition, we found sex-specific reductions in the rewarding properties of
morphine and the aversive components of naloxone-precipitated morphine withdrawal.
Further cross-species analysis will allow us to investigate mechanisms and adaptations
present in humans carrying this SNP.
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INTRODUCTION
Mu-opioid receptors (MOPR) are integrally involved in the modulation of several
pathways including pain, stress, and drug reward. Genetic mutations of the MOPR alter
endogenous and exogenous opioidergic function, thus influencing behavior. A single
nucleotide polymorphism (SNP) in exon 1 of the µ-opioid receptor gene (OPRM1), in
which an adenine to guanine substitution (A118G) exchanges an asparagine for an
aspartic acid at a putative N-glycosylation site (N40D), is common in persons of
European (15–30%) and Asian ancestry (49–60%), with lower prevalence in African
American and Hispanic populations (Bergen et al., 1997; Gelernter et al., 1999; Tan et
al., 2003). The A118G SNP has been associated with an altered vulnerability to opioid
addiction (Ray and Hutchison, 2004; Drakenberg et al., 2006; van den Wildenberg et al.,
2007), a decreased response to opioid-induced analgesia (Chou et al., 2006b; Sia et al.,
2008), and an enhanced response to therapies for alcohol (Ray and Hutchison, 2007;
Anton et al., 2008) and nicotine addiction (Lerman et al., 2004). However, some
association studies report divergent effects (Zhang et al., 2006b; Glatt et al., 2007), as
well as sex-specific associations (Fillingim et al., 2005; Ray et al., 2006; Munafo et al.,
2007), underscoring the need to understand the functional significance of this SNP.
Examination of the A118G variant in heterologous expression systems has
yielded inconsistent results. Initial in vitro studies indicated that expression of the human
G118 MOPR variant in AV-12 cells increases the binding affinity of !-endorphin to 3fold higher than that of the human A118 MOPR and results in higher potency for
activation of G protein-coupled potassium channels (Bond et al., 1998), suggesting a gain
of function of the receptor. However, other studies report no differences in agonist
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binding, functional coupling, or desensitization (Beyer et al., 2004). Using an allelic
expression assay, Zhang and colleagues (Zhang et al., 2005) found a 1.5-fold reduction in
allele-specific mRNA expression in post-mortem brain tissue and also a 10-fold reduction
in protein levels in CHO cells expressing the G118 variant, supporting a loss of function
of the receptor. More recent data support this claim, showing lower surface receptor
expression, decreased forskolin-induced cyclic AMP activation, and lower agonistinduced MOPR activation in cell culture systems expressing the G118 allele (Kroslak et
al., 2007). Discrepancies in the in vitro findings established the rationale for generating a
mouse model to examine the molecular, pharmacological, and behavioral significance of
this polymorphism in humans. Thus, we generated a mouse possessing the equivalent
SNP (A112G), which corresponds to a similar amino acid (N38D) substitution. Due to
high homology between mouse and human sequences at the nucleotide (86.9%) and
amino acid level (92.3%), similar gene expression levels between human and mouse
(Genomics Institute, Novartis Research Foundation; http://symatlas.gnf.org), as well as
conserved

chromosomal

synteny

(http://genome.ucsc.edu/cgi-bin/hgTracks),

we

generated the mouse equivalent of the human SNP rather than replacing the mouse
Oprm1 gene with the human OPRM1 gene in exon 1.
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RESULTS
Generation of the A112G mouse The derivation of the Oprm1 A112G mouse was
accomplished using a bacterial artificial chromosome (BAC) containing the entire Oprm1
locus derived from C57BL/6 mouse DNA (PAC/BAC Resource, Oakland, CA) (Fig. S1).
Mating A112G heterozygous mice produced offspring of each genotype (A/A: 32.6%,
A/G: 47.7%, and G/G: 19.7%, n = 700). Though G/G births were below expected
Mendelian rates (%2 = 24.6), there were no noticeable deficits in overall size or health, nor
were there differences in rates of perinatal mortality between genotypes or sexes
(unpublished observations). A/A and G/G homozygous mice of both sexes were used for
all molecular, biochemical, and behavioral assays.
MOPR expression and function We evaluated the expression and function of the
MOPR using a variety of molecular and pharmacological techniques. MOPR mRNA was
reduced in G/G mice in several brain regions related to pain, stress, and reward (main
effect of genotype, F1,77 = 71.018, p < 0.0001; Fig. 1a). Using primers designed to anneal
to different regions of the Oprm1 gene both 5’ and 3’ of the modified SNP, we found
similar reductions in mRNA (primer $ genotype interaction, F2,42 = 3.416, p = 0.04; Fig.
S2). The A to G substitution in these mice eliminates one of the four putative Nglycosylation sites; thus, the observed decrease in MOPR protein size in G/G mice may
reflect the reduction in the extent of N-linked glycosylation (Fig. 1b). In addition to a
lower molecular weight, total MOPR protein levels were reduced in G/G animals in the
thalamus, a region highly enriched in these receptors (t20 = 3.881, p = 0.0009; Fig. 1c).
Whole brain saturation binding using [3H]DAMGO showed decreases in receptor number
(Bmax) in G/G animals (effect of genotype F1,8 = 8.161, p = 0.02; Table 1). These data are
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in accordance with previous studies showing decreased cell-surface [3H]DAMGO
binding in AV-12 and HEK293 cells stably expressing the G118 variant (Beyer et al.,
2004; Kroslak et al., 2007). Kd values of [3H]DAMGO for the MOPR were similar
among the four groups of mice (Table 1). Analysis of brain region-specific binding using
a single concentration of [3H]DAMGO (3 nM) revealed decreased specific receptor
binding in the thalamus of G/G animals compared with their A/A counterparts (t20 =
3.170, p = 0.005; Fig. 1d). Using whole brain membranes, we determined the binding
affinities of #-endorphin, morphine, and naloxone by competitive inhibition of
[3H]DAMGO binding and found no alterations between genotypes or sexes (Table 1).
Behavioral responses to acute morphine administration In C57BL/6 mice, acute
morphine elevates locomotor activity(Crawley et al., 1997); accordingly, we observed a
robust increase in locomotor activity in A/A mice over the course of a 120-min session
following saline or morphine administration. In contrast, G/G mice failed to exhibit
morphine-mediated hyperactivity (time $ treatment $ genotype interaction, F11,649 =
11.108, p < 0.0001; Fig. S3a). There was no difference in locomotor activity between
genotypes during the 30-min baseline test or following saline administration, suggesting
that the alterations in activity are specific to morphine effects and not reflective of a
general locomotor deficit. Additionally, there was no difference in activity between males
and females in either genotype or treatment group (treatment $ genotype interaction, F1,59
= 16.076, p = 0.0002; Fig. S3b). Since morphine can have hypolocomotor actions at high
doses, it is possible that the decrease in activity in the G/G animals could result from a
heightened sensitivity to morphine. Thus, we evaluated the locomotor response to a low
dose of morphine (1 mg/kg). Neither of the genotypes or sexes displayed elevated activity
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in response to a low-dose morphine administration, indicating that the A112G SNP does
not confer an enhanced sensitivity (Fig. S3c,d). Morphine has been shown to elicit
enhanced locomotor-activating effects (behavioral sensitization) with repeated,
intermittent administrations (Babbini and Davis, 1972; Mickiewicz et al., 2009). Indeed,
A/A animals showed behavioral sensitization following repeated morphine injections,
while G/G animals did not (day $ genotype $ treatment interaction, F6,138 = 9.688, p <
0.0001; Fig. 2). Under these conditions, in which animals habituated to the testing
chambers, morphine elevated locomotor activity in the G/G animals, though this response
was greatly reduced compared to A/A animals (Fig. 2).
Opiate analgesics are widely used for pain management, but individual
differences in opiate-sensitivity can alter effective treatment. Clinical findings
demonstrate that individuals carrying the G118 allele report greater pain sensation (Sia et
al., 2008) and require higher doses of morphine to alleviate pain following surgery (Chou
et al., 2006a; Chou et al., 2006b; Reyes-Gibby et al., 2007; Sia et al., 2008). Therefore,
we used the hot-plate assay to evaluate basal nociceptive responses and morphinemediated antinociception in mice with the A112G SNP. Using a cumulative dosing
paradigm, in which animals were injected with increasing doses of morphine and
evaluated for morphine-mediated antinociception at 30-min intervals (Sora et al., 1997),
G/G mice showed a significantly lower maximal possible effect of morphine (%MPE) at
higher doses (genotype $ dose interaction, F1,63 = 5.348, p = 0.02; Fig. 3a). There were
no baseline differences in hind-paw lick latency, suggesting that the G/G mice do not
have a decreased pain threshold. However, when testing at a higher temperature (58°C), a
difference was detected in baseline jumping behavior (main effect of genotype, F1,63 =
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5.348, p = 0.02, Fig. S4a) along with a decrease in morphine-mediated antinociception
(main effects of genotype, F1,30 = 24.310, p < 0.0001 and sex, F1,30 = 4.356, p = 0.05; Fig.
S4b). Following 7 days of twice daily morphine injections (10 mg/kg), all animals
showed a reduced effect of morphine (day $ genotype $ treatment interaction, F1,48 =
4.801, p = 0.03; Fig. 3b), suggesting that although the acute antinociceptive properties of
morphine are diminished, tolerance to repeated administration remains intact.
The use of morphine as an analgesic is limited by the abuse liability of the drug
engendered by its ability to activate the reward pathway. In mice, the rewarding
properties of morphine can be demonstrated through the development of a conditioned
place-preference to environments paired with morphine. As expected, A/A animals
showed a robust preference for morphine-paired environments. G/G males showed a
preference for morphine-paired environments equivalent to that of the A/A mice. In
contrast, G/G females did not show a preference for the morphine-paired environment
(treatment $ genotype $ sex interaction, F1,44 = 3.958, p = 0.05; Fig. 4). The variable
effect of the A118G SNP in males and females has been reported in clinical studies of
nicotine addiction and pain response (Fillingim et al., 2005; Ray et al., 2006; Munafo et
al., 2007), but not for opioid reward (Compton et al., 2003).
Behavioral responses to withdrawal from chronic morphine exposure Chronic
morphine exposure can cause both physical and psychological dependence. Following
chronic morphine administration, male and female mice of both genotypes demonstrated
physical dependence, as measured by the presence of somatic signs following naloxoneprecipitated morphine withdrawal (main effect of sex, F1,18 = 7.537, p = 0.01, with no
contribution of genotype; Fig 5a). Psychological dependence was measured using a
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similar conditioning paradigm as was used to evaluate reward. Animals were implanted
with subcutaneous morphine or placebo pellets three days prior to receiving a single
naloxone (0.1 mg/kg, s.c.) administration in one chamber of a two-chamber conditioning
apparatus. All mice avoided environments associated with naloxone-precipitated
morphine withdrawal (main effect of treatment, F1,76 = 20.206, p < 0.0001; Fig. 5b).
Further analysis, however, shows that A/A females spent significantly less time on the
side of the chamber paired with naloxone-precipiated morphine withdrawal than did G/G
females (chronic treatment $ genotype $ sex interaction, F1,76 = 4.810, p = 0.03; Fig. 5b).
In contrast, there were no place aversion differences between male A/A and G/G mice.
Interestingly,

the

placebo-treated

G/G

females

also

avoided

naloxone-paired

environments compared to placebo-treated A/A females, while there were no differences
in males between genotypes. Together, these studies demonstrate that, in contrast to the
physical withdrawal signs, the psychological aversion associated with acute withdrawal
in morphine-dependent mice is altered by the G112 allele in females only.
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DISCUSSION
The A118G SNP has been implicated in a variety of pain sensitivity and drug
addiction phenotypes in humans. Specifically, carriers of the G118 allele show an
elevated sensitivity to pain and a reduced analgesic response to opioid administration.
Additionally, the G118 allele has been associated with increased efficacy of treatments
for alcohol and nicotine dependence. An understanding of the mechanisms underlying
these alterations is essential for developing alternative pain therapies for carriers of the G
allele or treatments for addiction that take advantage of the apparent benefit conferred by
this SNP. To clarify the functional mechanisms linking the OPRM1 A118G to some of
these phenotypes, we developed a knock-in mouse that possesses the mouse-equivalent
SNP in the MOPR gene (Oprm1 A112G).
Functional knock-in technology using Cre-loxP homologous recombination
allows for the generation of mouse models of human mutations or polymorphisms
(Roebroek et al., 2006). To prevent interference with normal transcriptional control, most
models have removed the selection marker resulting in a residual loxP site in the targeted
gene, which has not been shown to alter expression (Chen et al., 2006). In the present
mouse model, the G112-targeted allele did reduce both mRNA and protein expression in
some brain regions; however, SNPs in transcribed regions, specifically the A118G SNP,
have been shown to affect mRNA processing and turnover (Zhang et al., 2005; Johnson
et al., 2008). Thus, while we cannot rule out the potential effect of the loxP site as
contributing to reductions in mRNA and protein, the fact that these mice displayed
similar molecular and behavioral phenotypes to human carriers of the G118 allele
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provides evidence that this SNP indeed has functional consequences and that this mouse
could serve as a valuable tool in identifying the effects of these changes.
It has been contested whether the A118G SNP confers a gain or loss of function.
Studies reporting elevations in biochemical or behavioral traits (e.g., increases in
maternal attachment in primates (Barr et al., 2008) or cortisol responses in humans
(Chong et al., 2006)) typically cite elevations in #-endorphin binding (Bond et al., 1998)
as a potential mechanism. Alternatively, studies reporting deficits in behavior (e.g.,
decreased nicotine reward (Ray et al., 2006)) typically cite decreases in MOPR
expression (Zhang et al., 2005) as explanation for the effects. In the present study, we
found evidence suggesting that the consequences of this SNP cannot be evaluated as a
simple gain or loss of function. We did not find evidence suggesting altered affinity to
MOPR agonists, though we did corroborate studies showing decreased MOPR expression
by demonstrating decreases in mRNA, protein, and receptor number. In line with
decreased MOPR levels, G/G mice showed deficits in the hyperlocomotor and
antinociceptive actions of acute morphine administration; however, not all behaviors
showed deficits despite these reductions. This is most evident in the conditioned reward
and aversion studies in which only females demonstrated an altered behavioral response.
On the other hand, physical morphine withdrawal signs were similar between genotypes
for both sexes. Previous studies have demonstrated a disassociation between the physical
and aversive components of precipitated morphine withdrawal (Harris and Aston-Jones,
1993; Schulteis et al., 1994), suggesting that the alterations caused by this SNP is
dependent on the circuitry involved.
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Distinctions between genotypes do not appear to be dependent on the timing or
duration of morphine administration. G/G mice showed a significant, albeit diminished,
antinociceptive effect of acute morphine treatment. This effect decreased with repeated
morphine exposure, demonstrating that these mice develop tolerance similar to A/A mice.
Furthermore, G/G mice showed a significant, yet diminished, hyperlocomotor effect of
acute morphine treatment. However, repeated morphine exposure did not increase this
response, demonstrating that G/G mice do not develop locomotor sensitization.
Therefore, the mechanisms underlying the development of tolerance and sensitization
may be differentially influenced by the Oprm1 SNP. Loss of the delta-opioid receptor, for
instance, results in elevated sensitization and diminished tolerance to morphine (Chefer
and Shippenberg, 2009). Though we did not investigate changes in the expression and
function of other opioid receptors, it is possible that compensatory upregulation or altered
dimerization of these receptors could contribute to some of the altered behaviors of the
G/G mice.
Morphine has varying potencies in males compared with females, depending on
the assay (for review, see (Craft, 2008)). Recently, differences in MOPR receptor levels
in rat brain have been identified as essential for sex differences in morphine analgesia
(Loyd et al., 2008). Estrogen modulation of MOPRs is supported by in vivo positron
emission tomography (PET) imaging studies with [11C] carfentanil. Pre-menopausal
women have approximately 25% greater availability of MOPRs than men in cortical and
subcortical areas (Zubieta et al., 1999; Zubieta et al., 2002), a difference that disappears
after menopause (Zubieta et al., 1999). The sex-differences we observed in morphine
reward and withdrawal, however, cannot be explained by altered levels of MOPRs, as
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these reductions were equivalent across sexes. To further explore hormonal modulation in
this phenotype, studies requiring estrogen depletion of females or feminization of males
harboring this SNP will be required. To date, human genetic studies have not been
designed a priori with adequate power to examine the sex-dependent effects of the
OPRM1 A118G SNP on behavior. The current data suggest such analysis is warranted.
Genetic association studies in psychiatry and addiction are plagued by
nonreplications. However, there is a critical mass of positive studies linking the OPRM1
A118G SNP with opioid, alcohol, and nicotine dependence, and subsequent treatment
responses. Data obtained from the A112G mice provide compelling evidence that this
type of a translational cross-species model is important for complete functional
characterization of genetic variants. Future studies utilizing this mouse model could
serve as a valuable tool in determining the mechanisms underlying responses to a variety
of drugs of abuse and in developing personalized therapies based on genotype.
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MATERIALS AND METHODS
Animals All mice (8–15 weeks, 18–30 g) were group housed and maintained on a 12h/12-h light/dark cycle with food and water available ad libitum in accordance with the
University of Pennsylvania Animal Care and Use Committee. For a complete description
of the derivation of Oprm1tm1Jabl mice, see supporting information. All experimental
testing sessions were conducted between 0800 hours and 1700 hours, with animals
randomly assigned to treatment conditions and tested in counterbalanced order. Both
male and female mice were used in all studies except for morphine locomotor
sensitization, in which only males were utilized. Male and female data were combined
when there were no statistical contributions of sex. Separate, näive cohorts were used for
behavioral experiments, except for acute locomotor (Fig. S3), hot-plate (Fig. S4), and
physical withdrawal (Fig. 5a) studies, in which one cohort of animals was used for all
three experiments conducted in the order listed and separated by at least one week.
Separate cohorts of animals were used and the data combined for the following
experiments: CPP (Fig. 4), CPA (Fig 5), acute locomotor activity (Fig. S3), and 58° C
hot-plate (Fig. S4), as there were no statistical differences within groups measured
between cohorts.
Drugs For acute drug administration, morphine sulfate was obtained from NIDA Drug
Supply (Research Triangle Park, NC) and naloxone hydrochloride was obtained from
Sigma Aldrich. Both drugs were dissolved in 0.9% saline and administered
subcutaneously at a volume of 0.1 mL/10 g body weight. Morphine dependence was
achieved by subcutaneously implanting a single placebo (cellulose) or morphine (25 mg
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morphine base) pellet (NIDA Drug Supply, Research Triangle Park, NC) in the dorsal
surface of mice under general isoflurane anesthesia for three days prior to testing.
Quantitative real-time PCR For RNA isolation and cDNA synthesis, mice were killed
by cervical dislocation and brains were rapidly removed and dissected on ice. Brains
were first sliced using a mouse brain matrix into 1mm slices. Specific regions were
identified and macrodissected using their approximate mouse stereotaxic coordinates
(AMYG and HIPP, bregma "1.2mm; BNST and CTX, bregma +0.26mm; NAc, bregma
+1.10mm; VTA, bregma "3.64mm). The hypothalamus was removed from the ventral
side of the brain prior to placement in the mouse brain matrix. RNA was isolated from
brain tissue using TRIzol/chloroform in conjunction with an RNeasy Mini kit (Qiagen).
cDNA was synthesized using Oligo dT primer (Operon) and Superscript II reverse
transcriptase (Invitrogen). Taqman QPCR multiplex reactions were assembled using the
Taqman Universal PCR Master Mix (Applied Biosystems) along with 300nM primers
(final concentration). All quantitative real-time polymerase chain reactions (QPCR) were
run using the Stratagene MX3000 and MXPro QPCR software with cycling parameters
set at 95°C for 10min followed by 40 cycles of 95°C (30s) and 60°C (1min). All
reactions were performed in triplicate and the median cycle threshold was used for
analysis. The mRNA levels of target genes were normalized to the housekeeping gene,
TATA binding protein (TBP). Primers used in Fig 1 were found 3’ of the knock-in and
spanned exon 1 and exon 2 (5’: caccatcatggccctctatt; 3’: caaaatgaagactgccacca).
Brain membrane preparation Frozen mouse whole brains or thalami were
homogenized in ~8-volume 25 mM Tris-HCl buffer/pH7.4 containing 1 mM EDTA and
0.1 mM PMSF on ice and then centrifuged at ~100,000g for 30 min. Pellets were twice
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rinsed with 25 mM Tris-HCl buffer and re-suspended in 0.32 M sucrose in 50 mM TrisHCl/pH7. Suspended membranes were passed through a 26.5G needle for 5 times and
then frozen at -80oC.
Western Blot Membranes were prepared from thalami of A/A mice, G/G mice, and
MOPR knock-out mice. The MOPR knock-out mice used were originally developed in
the lab of Dr. John Pintar by disruption of exon 1 of the Oprm1 gene through
homologous recombination (Schuller et al., 1999). Membrane proteins were loaded (15
µg per lane) for SDS-PAGE and western blot was performed with the MOPR antibody,
anti-µC [against the MOPR (383-398) peptide] (1:5,000, final 0.26 µg/ml), followed by
goat anti-rabbit IgG conjugated with HRP (1:5,000), and then reacted with enhanced
chemiluminescence (ECL) western blotting detection reagents (Huang et al., 2008).
Images were captured with a FujiFilm LAS-1000 Imaging System. After a brief wash, the
same blot was then incubated with mouse anti-GAPDH-HRP-conjugated (1:10,000)
(Abcam) followed by ECL reagents. Quantification of MOPR-immunoreactivities was
carried out by densitometry analysis with the ImageGauge software for Fuji Imaging
System. MOPR immunoreactivity in each lane was normalized against that of GAPDH.
MOPR Ligand Binding Binding assays were performed as previously described (LiuChen et al., 1995) with some modifications. Mouse brain membranes were incubated at
room temperature for 30 min with 100 mM NaCl and 100 µM GDP in 50 mM Tris-HCl
buffer (pH7.4) containing 1 mM EDTA (TE buffer) and washed three times with the TE
buffer. Binding was performed in TE buffer containing 5 mM MgCl2 for 2.5~3 hrs at
room temperature in order to convert receptors to high affinity states. Saturation binding
of [3H]DAMGO to MOPRs in whole brain membranes was performed with seven
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concentrations of [3H]DAMGO (ranging from 0.1 to 8.0 nM), and Kd and Bmax values
were determined by non-linear regression curve fit with one site binding (GraphPad
Prism). For binding to MOPR in thalamus membranes, a single concentration of
[3H]DAMGO was used (3 nM). Competitive inhibition of [3H]DAMGO (1.0 nM) binding
by #-endorphin, morphine or naloxone was performed in the absence or presence of
various concentrations of each ligand. Ki values were determined by non-linear
regression curve fit of one site competition (GraphPad Prism). Nonspecific binding was
measured in the presence of naloxone (1.0 #M). Each binding assay was carried out in
duplicate in a final volume of 0.5 ml with 0.2–0.4 mg protein/tube for whole brain
binding or 0.1 mg protein/tube for thalamus binding. Incubations were terminated by
filtration through Whatman GF/B filters under vacuum.
Locomotor Activity Locomotor activity was analyzed in a "home cage" activity
monitoring system (MedAssociates). The testing cage, which was identical in dimension
to the home cage, was placed in a photobeam frame (30 $ 24 $ 8 cm) with two levels of
sensors arranged in an 8-beam array strip. A small amount of fresh bedding was scattered
on the cage floor. Locomotor sensitization: animals were tested every 2–3 days for 120
minutes following an injection of saline or morphine (10 mg/kg, s.c.). On treatment days
1–3, all animals were administered saline. On days 4–9, animals received either morphine
or saline, according to their treatment group. Beam break data were read into
MedAssociates personal computer-designed software and monitored at 10-minute
intervals.
Hot-Plate The nociceptive threshold for analgesia was examined with a hot-plate
analgesia meter (Columbus Instruments). The hot-plate provided a constant 55° C (Fig.
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3) or 58° C (Fig. S4) surface, temperatures low enough to avoid harming the mice, but
high enough to be uncomfortable for a saline-treated animal. A small plastic cage
surrounding the hot-plate prevented the animal from leaving the plate surface.
Cumulative dosing (Fig. 3a): animals were first placed on the hot-plate and the latency to
lick the hind-paw or jump was recorded. Upon displaying one of these behaviors or upon
reaching the predetermined cut-off time (60 s), the animals were immediately removed
from the hot-plate, injected with the first dose of morphine, and returned to their home
cage. Animals were retested on the hot-plate and immediately injected with the next
morphine dose at 30-minute intervals. Animals received doses of 0, 1, 2, 7, 20, and 20
mg/kg; any animals that did not complete the 60-second trial without licking or jumping
at the highest dose received an additional 20 mg/kg injection at the usual dosing
schedule. Tolerance (Fig. 3b): animals were injected twice daily for 8 days with
morphine (10 mg/kg) or saline, according to treatment group, and tested for
antinociception 30 minutes following the a.m. injection. The latency to lick the hind-paw
or jump was recorded and a maximum test-duration set at 60 seconds.
Conditioned Place Preference Place-conditioning boxes consisted of two chambers (20
$ 20 $ 20 cm), one with stripes on the wall and a metal grid floor and the other with gray
walls and a metal patterned floor. A partition with an opening separated the two chambers
in each box, but allowed access to either side of the chamber. This partition was closed
off during the pairing days. Preconditioning Phase (day 1): Animals were placed in the
boxes and allowed to roam freely throughout both chambers for 15 min; time spent in
each chamber was recorded. These data were used to separate the animals into groups of
approximately equal bias. Conditioning Phase (days 2–9): Animals received 8 days of
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once-a-day pairings in which an animal was injected with morphine (10 mg/kg) or saline
and then immediately placed into one chamber for 30 minutes. On the following day,
animals were injected with either saline or morphine, depending on what they had
received on the previous day, and placed in the opposite chamber. Drug pairings were
divided such that half of the animals received morphine injections on odd days while the
other half received morphine on even days; non-drug paired animals received saline
injections throughout the conditioning phase. Drug-paired chambers were randomized
among all groups. Testing Phase (day 10): Animals were all given a saline injection and
allowed to roam freely between the two chambers; the amount of time spent in each
chamber was recorded.
Conditioned Place Aversion The CPA test was performed similarly to the CPP test with
the following differences. Preconditioning phase (day 1): Three days following
implantation of morphine or placebo pellets, animals were placed in the boxes and
allowed to explore both chambers in order to test for preexisting biases. Conditioning
phase (days 2–3): On day 2, all animals were injected with saline and confined to one
chamber for 30 minutes. On day 3, all animals were injected with naloxone (0.1 mg/kg,
s.c.) and confined to the opposite chamber for 30 minutes. Test phase (day 4): Animals
were injected with saline and allowed to explore both chambers; the amount of time spent
in either chamber was recorded.
Somatic Withdrawal Signs Three days following implantation of morphine or placebo
pellets, animals were placed on cotton pads inside of a clear plastic cylinder with an open
top. Animals were allowed to habituate for 30 minutes prior to receiving a subcutaneous
injection of naloxone (0.1 mg/kg). The number of occurrences of jumping, paw tremor,
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genital licking, backing up, and gnawing was recorded. Additionally, the presence or
absence of the following symptoms was recorded in 5-minute bins for the 30-minute test:
ptosis, resting tremor, diarrhea, and teeth chatter. Withdrawal scores were calculated as
the sum of all occurrences of somatic signs displayed during the 30-minute test.
Analysis When comparing multiple effects, analyses were performed using two- or threeway analysis of variance (ANOVA) tests (repeated measures tests were utilized when
comparing multiple time points) with significant F values reported in the text.
Bonferroni/Dunn post-hoc tests were used to compare significant interactions between
main effects. When comparing differences between genotypes for only one effect,
unpaired t-tests were utilized with significant t values reported in the text. Statistical
significance was set at p $ 0.05.
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FIGURE LEGENDS
Figure 1. MOPR expression is decreased in A112G knock-in mice. (a) MOPR
mRNA, as measured by Real Time RT-PCR and normalized against TATA binding
protein (TBP), in the periaqueductal grey (PAG), hypothalamus (Hypo), ventral
tegmental area (VTA), nucleus accumbens (NAc), and cortex (Ctx) (mean ± SEM, n = 78; * p < 0.05, ** p < 0.01, *** p < 0.001, † p < 0.0001 compared to A/A, Bonferroni/Dunn).
(b) A representative immunoblot of MOPR in membranes prepared from thalami of A/A
mice, G/G mice, and MOPR -/- mice and probed with the MOPR antibody shows
decreased molecular weight of MOPR protein in G/G mice. (c) Quantification of MOPRimmunoreactivities, normalized against GAPDH (mean ± SEM, n = 11;

***

p < 0.001

compared to A/A). (d) Binding of [3H]DAMGO (3 nM) in thalamus membranes (0.1
mg/tube). Data are presented as specific binding/tube (dpm) for each sample run in
duplicate (mean ± SEM, n = 11; ** p < 0.01 compared to A/A).
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Figure 2.1
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Figure 2. Morphine-mediated hyperlocomotion is blunted in G/G mice. Saline was
administered to all groups on days 1–3 and morphine was administered on days 4–9
(saline control groups received saline injections on all 9 days). Results are presented as
total activity counts for the 120-min post-injection test (mean ± SEM, n = 6-7; * p < 0.05,
**

p < 0.01, *** p < 0.001, † p < 0.0001 compared to saline-injected controls; + p < 0.01, ++

p < 0.0001 compared to the average of days 1–3, Bonferroni/Dunn).
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Figure 2.2
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Figure 3. Morphine-mediated antinociception is decreased in G/G mice while
tolerance to repeated exposure remains intact. (a) Morphine-mediated antinociception,
as measured by hind-paw lick latency on a 55º C hot-plate assay using a cumulativedosing paradigm, was significantly reduced in G/G mice. Results are presented as percent
maximal possible effect (MPE) [(morph jump latency – saline jump latency)/(total time –
saline jump latency) $ 100] (mean ± SEM, n = 18; *** p < 0.001, † p < 0.0001 compared
to G/G mice). (b) Tolerance to morphine-mediated (10 mg/kg) hot-plate antinociception
was present in both A/A and G/G mice. Results are presented as percent maximal
possible effect (MPE) [(morph jump latency – baseline jump latency)/(total time –
baseline jump latency) $ 100] (mean ± SEM, n = 12-14; * p < 0.05, ** p < 0.01 compared
to saline-treated controls;

+

p < 0.05,

++

p < 0.01 compared to Day 8,

compared to G/G mice treated with morphine, Bonferroni/Dunn).
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†

p < 0.0001

Figure 2.3
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Figure 4. Female G/G mice failed to show a conditioned place-preference to
morphine-paired environments (10 mg/kg). Results are presented as the difference in
time spent in drug-paired environments compared to non drug-paired environments on
the test day minus the difference in time from the preconditioning day (mean ± SEM, n =
6–8; * p < 0.05,

**

p < 0.01 compared to saline-treated controls;

morphine-treated A/A females and G/G males, Bonferroni/Dunn).
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+

p < 0.05 compared to

Figure 2.4
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Figure 5. Dissociation of the physical and affective components of naloxoneprecipitated morphine withdrawal (a) A/A and G/G mice displayed similar somatic
signs of naloxone-precipitated (0.1 mg/kg) withdrawal. Results are presented as the
withdrawal score calculated by summing the total number occurrences of jumping, paw
tremor, genital licking, backing up, gnawing, ptosis, resting tremor, diarrhea, and teeth
chatter (mean ± SEM, n = 5–6;

*

p < 0.05 compared to male A/A and G/G). (b)

Naloxone-precipitated morphine withdrawal-induced place aversions were reduced in
G/G females. Additionally, placebo-treated G/G females displayed aversion to naloxonepaired environments compared to A/A females. Results are presented as the difference in
time spent in drug-paired environments compared to non drug-paired environments on
the test day minus the difference in time from the preconditioning day (mean ± SEM, n =
8–12; * p < 0.05 compared to morphine-treated A/A females;
compared to placebo-treated A/A females, Bonferroni/Dunn).
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+

p < 0.05,

++

p < 0.0001

Figure 2.5
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TABLE LEGENDS
Table 1. Kd and Bmax values were calculated from saturation binding of [3H]DAMGO
using whole brain membranes. Competitive inhibition by #-endorphin, morphine and
naloxone of [3H]DAMGO (1.0 nM) binding was conducted to determine Ki values. For
each independent experiment, two mouse brains were pooled (0.2–0.4 mg membrane
proteins/tube) for one saturation curve and three competition curves. Each value
represents the binding for three independent experiments performed in duplicate (mean ±
SEM; * p < 0.05, compared to A/A).
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Table 2.1 Expression Levels and Ligand Binding Affinities of MOPR in A/A and
G/G mice.

[3H] DAMGO
A/A male
A/A female
G/G male
G/G female

Bmax
(fmol/mg protein)
158 ± 11.7
182 ± 5.0
142 ± 13.7*
114 ± 22.5*

#-Endorphin

Kd
(nM)
0.29 ± 0.03
0.26 ± 0.03
0.33 ± 0.02
0.33 ± 0.03
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1.9 ± 0.06
2.1 ± 0.28
1.6 ± 0.11
1.8 ± 0.18

Morphine
Ki
(nM)
2.4 ± 0.16
2.7 ± 0.25
2.9 ± 0.23
2.8 ± 0.31

Naloxone
2.9 ± 0.04
3.2 ± 0.12
2.7 ± 0.32
3.0 ± 0.27

SUPPORTING INFORMATION
Materials and Methods
Derivation of Oprm1tm1Jabl mice The construction of the A112G allele was
accomplished by using a bacterial artificial chromosome (BAC) containing the entire
Oprm1 locus derived from C57BL/6 mouse DNA (obtained from the PAC/BAC resource
in Oakland, CA; (clone RP23)). The region containing exon 1 and flanking introns was
used as the template for site-directed mutagenesis. The polymorphism in exon 1 was
constructed by changing the adenosine (A) nucleotide at position 112 of the mouse,
which corresponds to position 118 in the human sequence, to a guanosine (G). A second
mutation (T108C) was introduced which abolished a BstXI restriction site in order to
identify the mutated clones without affecting the aspartic acid encoded by the codon.
Mutations were verified by sequencing and restriction analysis. For the generation of the
targeting vector, two PCR fragments were cloned into plasmid pL452 (containing loxP
sequences and a Neomyocin-resistant cassette for later selection) flanking the loxP sites.
The first fragment (1.3kb) contained exon 1 with the point mutation and was cloned by
KpnI-EcoRI. The second fragment (650bp) corresponded to an intronic DNA sequence
located downstream of the fragment containing exon 1 and was cloned by NotI-SacII. A
plasmid was generated to retrieve a 10kb fragment containing the MOPR gene. A
fragment containing the modified exon 1, the neo cassette flanked by loxP sequences, and
the downstream fragment was recovered from vector pL452-MUT and electroporated
into EL250 cells containing the MOPR plasmid. This homologous recombination led to
the introduction of the point mutation, loxP sites, and neo cassette into the final targeting
construct. 100 mg of this vector was linearized with XmaI and electroporated into
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C57BL/6 ES cells (Chemicon Inc.). Putative recombinants were selected by neomycin
resistance. Initial screening of resistant clones was performed by PCR. Genomic DNA
from clones growing in 96-well plates served as the template for a first PCR reaction
using the primers NEO-F-KK-1 and PROBE-R. One µl from the first PCR product was
the template for a nested PCR using the primers NEO-F-KK-2 and PROBE-R-KKnested. Six clones out of 192 were identified as positive by PCR and, following rescreening by Southern blot, one clone was confirmed as correctly targeted. ES cells were
injected into C57BL/6 blastocysts, which were then implanted into pseudopregnant
females. Thirteen male chimaeras were obtained. Chimeric animals were mated with
C57BL/6 mice to produce heterozygous animals, which were then crossed with mice
expressing Cre recombinase to remove the neo cassette. Heterozygous offspring were
then mated to produce mice of all genotypes.
Quantitative real-time PCR Primers used in Fig S2 were in exon 1 5’ from the knock-in
(5’: ctggaacccgaacactcttg; 3’: gcaacttgcaggagctaagg), spanned exon 2 and exon 3 (5’:
cctctcttctgccattggtc; 3’: tgaaggcgaagatgaagaca), or spanned exon 3 and exon 4 (5’:
tcccaacttcctccacaatc; 3’: tagggcaatggagcagtttc).
Locomotor Activity Mice were placed in the chamber and baseline activity was recorded
for 30 minutes. Animals were then injected with saline or morphine (1 or 10 mg/kg, s.c.)
and placed back into the chambers and activity was recorded for 120 minutes.
Antinociception For baseline and acute morphine antinociception (Fig. S4), animals
were exposed to the hot-plate (58° C) and the latency to jump was recorded. Twenty-four
hours later, the test was repeated 15 minutes following an acute morphine (10 mg/kg,
s.c.)

or

saline

injection.

The

cut-off
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time

was

set

at

120

seconds.

Figure Legends
Figure S1. Generation and validation of Oprm1tm1Jabl mice (a) Schematic diagram of
the strategy used to replace exon 1 of the Oprm1 gene with the Oprm1 Asp38Asn variant.
For the variant, a point mutation has been made (A112G) which exchanges an asparagine
at position 38 for an aspartic acid. (b) Southern blot analysis of genomic DNA from one
embryonic stem-cell clone following digestion with BclI and hybridization with a
flanking genomic fragment as a probe, indicated in A, was used to detect homologous
recombination in the Oprm1 locus. The 10.9 kb wild type (+/+) and 3 kb (+/Asp) variant
DNA bands are indicated. (c) Sequencing the targeting vector confirms the A112G point
mutation that leads to the Asn38Asp amino acid change. (d) Gel electrophoresis of DNA
PCR products depicts wild-type (A/A), heterozygous (A/G), and homozygous (G/G)
mice. The difference in molecular weight for the wildtype (431 kb) and the mutant (327
kb) bands results from intronic DNA lost during generation of the targeting vector.
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Supplementary Figure 2.1
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Figure S2. MOPR mRNA is reduced in NAc when using primers targeting different
exons as measured by Real Time RT-PCR and normalized against TATA binding protein
(TBP) (mean ± SEM, n = 8;

**

p < 0.01,

Bonferroni/Dunn).
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***

p < 0.001 compared to A/A,

Supplementary Figure 2.2
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Figure S3. Reduction in locomotor-activating effects of morphine (a) Following 30
minutes of drug-free exploration, morphine administration (10 mg/kg) elevated
locomotor activity only in A/A mice. Results are presented as activity counts in 10-min
bins (mean ± SEM, n = 16–18; ** p < 0.01, *** p < 0.001, † p < 0.0001 compared to G/G
mice receiving morphine and A/A and G/G mice receiving saline, Bonferroni/Dunn). (b)
Total activity count alterations following an acute saline or morphine injection, as shown
in A, are not sex-dependent. (mean ± SEM, n = 8–9; † p < 0.0001 compared to G/G mice
receiving morphine and A/A and G/G mice receiving saline, Bonferroni/Dunn). (c) A
low-dose administration of morphine (1 mg/kg) did not alter activity during the 2-h test.
Results are presented as activity counts in 10-min bins and (d) over the entire session
(mean ± SEM, n = 6–8).
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Supplementary Figure 2.3
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Figure S4. Altered hot-plate responses (a) Baseline nociception, as measured by jump
latency on a 58º C hot-plate assay, was significantly reduced in G/G mice. Results are
presented as the latency to jump (in seconds) following placement on the hot plate (mean
± SEM, n = 16–18;

*

p < 0.05). (b) Morphine-mediated (10 mg/kg) hot-plate

antinociception was decreased in G/G mice. Results are presented as percent maximal
possible effect (MPE) [(morph jump latency – average saline jump latency)/(total time –
average saline jump latency) % 100] (mean ± SEM, n = 7–9; † p < 0.0001).
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Supplementary Figure 2.4
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CHAPTER 3: ALTERED HIPPOCAMPUS
NETWORK FUNCTION IN MICE WITH OPRM1
A118G SNP

Stephen D. Maguea, Jill R. Turnera, Greg C. Carlsonb, Julie A. Blendya,c
Department of Pharmacologya, Psychiatryb, and Abramson Cancer Centerc, University of
Pennsylvania School of Medicine, Philadelphia, PA 19104
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ABSTRACT
A single nucleotide polymorphism (SNP) in the human µ-opioid receptor gene
(OPRM1 A118G) has been widely studied for its association in a variety of drug
addiction and pain sensitivity phenotypes; however, the extent of these adaptations and
the mechanisms underlying these associations remain elusive. To clarify the functional
mechanisms linking the OPRM1 A118G SNP to altered phenotypes, we derived a mouse
model possessing the equivalent nucleotide/amino acid substitution in the Oprm1 gene.
These mice have reduced levels of MOPR expression in some, but not all, brain regions:
specifically, the levels of MOPRs in the hippocampus are not different between
genotypes. The hippocampus, which contains excitatory pyramidal cells whose activity is
highly regulated by a dense network of inhibitory neurons, serves as an ideal structure to
evaluate how putative receptor function abnormalities may influence alterations in circuit
function. Therefore, to investigate whether this SNP impacts a functional response in the
absence of reduced receptor levels, we utilized voltage-sensitive dye imaging in
hippocampal slices before and after MOPR stimulation with DAMGO. Utilizing several
analytical methodologies, we found that MOPR activation increased excitatory responses
in wild-type animals, an effect that was significantly reduced in animals possessing the
Oprm1 SNP. These data further support claims that this SNP results in a loss of receptor
function.
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INTRODUCTION
Mu-opioid receptors (MOPR) are integrally involved in the modulation of several
pathways including pain and drug reward. Genetic mutations of the MOPR alter
endogenous and exogenous opioidergic function, thus influencing behavior. A single
nucleotide polymorphism (SNP) in exon 1 of the µ-opioid receptor gene (OPRM1), in
which an adenine to guanine substitution (A118G) exchanges an asparagine for an
aspartic acid at a putative N-glycosylation site (N40D), has been associated with an
altered vulnerability to opioid addiction (Ray and Hutchison, 2004; Drakenberg et al.,
2006; van den Wildenberg et al., 2007), a decreased response to opioid-induced analgesia
(Chou et al., 2006a; Sia et al., 2008), and an enhanced response to therapies for alcohol
(Ray and Hutchison, 2007; Anton et al., 2008) and nicotine addiction (Lerman et al.,
2004). In vitro studies using a variety of cell lines expressing the G118 allele have
reported increased affinity of the receptor to the endogenous opioid !-endorphin (Bond et
al., 1998) and elevated ability of exogenous opioids to inhibit calcium currents (Margas
et al., 2007); however, these results were dependent on the cell type and transfection
method utilized and other studies have reported no differences in agonist binding,
functional coupling, or desensitization (Befort et al., 2001; Beyer et al., 2004).
Conversely, studies have reported decreases in MOPR mRNA (Zhang et al., 2005) and
cell surface expression of the receptor (Beyer et al., 2004; Zhang et al., 2005; Kroslak et
al., 2007), suggesting a loss of receptor function.
Discrepancies in the in vitro findings established the rationale for developing a
mouse model to examine the molecular, pharmacological, and behavioral significance of
this polymorphism in humans. Mice possessing the equivalent SNP (A112G) have
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decreases in MOPR expression and morphine-evoked behaviors, in addition to sexspecific deficits in the rewarding properties of morphine (see Chapter 2; Mague et al.,
2009). It was not determined, however, whether these behavioral effects resulted solely
from a decrease in receptor availability or if the SNP altered receptor functionality
independently from expression differences. For instance, both male and female mice
homozygous for the G112 allele (G/G) showed equivalent decreases in levels of MOPR
mRNA and protein expression in reward-related brain regions; however, only the female
mice showed decreases in morphine-conditioned place preference and naloxoneprecipitated morphine withdrawal-induced aversions.
Either a change in receptor number or receptor function could alter circuit-level
activity due to disregulated opioidergic modulation of target cells. In order to investigate
if alterations in receptor function were responsible for these changes, we evaluated circuit
function in the hippocampus, a region displaying similar MOPR expression between
genotypes and sexes. Structurally, the CA1 region of the hippocampus consists of a
single lamina of glutamatergic pyramidal cell bodies [stratum pyramidae (SP)], which
have distal apical dendrites that form synapses with entorhinal cortex axons of the
perforant path [stratum lacunosum moleculare (SLM)], proximal apical dendrites that
form synapses with Shaffer collateral axons from CA3 [stratum radiatum (SR)], and basal
dendrites which receive input from other pyramidal neurons [stratum oriens (SO)]. These
excitatory synapses are densely innervated by a variety of inhibitory interneurons, which
can be identified by the layer in which the soma resides, layers to which the axons
project, and the molecular constituents they express (for review, see Klausberger and
Somogyi, 2008). MOPRs are predominantly found on somatodendritic and axonal aspects
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of fast-spiking, parvalbumin (PV)-containing GABAergic basket cells (Drake and
Milner, 1999, 2002). PV cell bodies comprise approximately half of the GABAergic
neurons in SP and a smaller portion of the interneurons in the adjoining areas of SO and
SR (Kosaka et al., 1987; Freund and Buzsaki, 1996) and their axons project to SLM, SR,
and SO (Drake and Milner, 2002).
GABAergic modulation by these interneurons causes local inhibition of excitatory
responses in CA1. Specifically, activation of PV cells (e.g., SR stimulation by input from
Schaffer collaterals of CA3) leads to strong repolarization of the target pyramidal
neurons. This strong perisomatic GABAergic inhibition can induce fast changes in
neuronal polarity and gate cell firing at high frequencies (Csicsvari et al., 2003; Uhlhaas
and Singer, 2010). Since each PV basket cell targets many pyramidal cell afferents, they
are well-situated to modulate CA1 output. Indeed, oscillatory activity in CA1 reflects
pyramidal neuron synchronization resulting from the interactions between these cells and
the highly interconnected network of GABAergic interneurons (Bartos et al., 2007),
particularly the fast-spiking PV cells (Cardin et al., 2009; Lodge et al., 2009). Thus,
regulation of excitatory output by PV neurons may, in part, underlie network synchrony
and gamma-band oscillatory activity (Whittington and Traub, 2003), which has been
shown to influence memory storage and retrieval (Montgomery and Buzsaki, 2007;
Montgomery et al., 2009). Activation of MOPRs, by endogenous or exogenously-applied
opioids, located on somata and axonal aspects of the PV interneurons hyperpolarizes
these cells and decreases GABAergic neurotransmission, thereby disinhibiting
glutamatergic neurons and providing net excitatory activity (Neumaier et al., 1988;
Glickfeld et al., 2008). This loss of GABAergic modulation induced by MOPR activation
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has been shown to reduce high-frequency gamma-band oscillations in the hippocampus
(Whittington et al., 1998) and cortex (Sun et al., 2006; Zuo et al., 2007).
CA1 GABAergic modulation by MOPR stimulation has also been shown to be
necessary for the rewarding effects of morphine. GABA agonists administered into the
CA1 region of the hippocampus – functionally bypassing morphine-mediated GABAA
inhibition – reduced preferences to morphine-paired environments. Conversely, GABAA
antagonists administered directly into the CA1 – functionally mimicking MOPR
stimulation – elicited a preference to environments paired with sub-threshold doses of
morphine (Rezayof et al., 2007). Together, these experiments demonstrate the necessity
of GABAergic modulation by morphine in the CA1 for the expression of morphine
reward. In previous studies of the A112G mice, we found a sex-specific deficit in the
rewarding properties of morphine, in which the G/G male mice preferred morphinepaired environments equivalently to A/A animals, whereas the G/G females did not. The
lack of concomitant MOPR expression-level differences in reward-related brain regions
suggested that receptor-signaling differences could be mediating these alterations.
Specifically, sex-specific alterations in GABAergic modulation of excitatory responses
due to aberrant MOPR regulation could alter hippocampal network activity and,
subsequently, disrupt morphine-conditioned preferences.
In order to better understand the synaptic and circuit-level alterations conferred by
the A112G SNP, we employed voltage-sensitive dye imaging techniques in hippocampus
slice preparations to evaluate basal and opioid-stimulated neuronal responses. The
activity of pyramidal cells provides a read-out of net circuit effects on hippocampal
output neurons. CA1 pyramidal cells supply an especially clear view of inhibition
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because they do not generate recurrent excitation; accordingly, excitatory postsynaptic
potentials (EPSPs) induced by afferents are followed almost exclusively by locally
induced inhibitory postsynaptic potentials (IPSPs). As a result, CA1 IPSPs in the
pyramidal cells form a temporally distinct and therefore measurable VSDi component
(Ang et al., 2005; Carlson and Coulter, 2008). In these studies, we found that baseline net
circuit activity elicited by a single excitatory stimulus was similar between wild-type A/A
mice and the G/G mice. However, while DAMGO administration increased net activity in
slices from A/A mice, these effects were significantly attenuated in G/G mice, suggesting
a loss of function of the MOPR. These data, which support clinical findings of decreased
responses to opioidergic modulation, are the first to show functional receptor deficits
resulting from this SNP irrespective of expression-level changes.
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MATERIALS AND METHODS
Animals. All experiments utilized adult male and female mice (10-20 weeks of age; 2035 g) homozygous for the A112 (wild-type) or G112 (knock-in) allele [for detailed
description of generation of Oprm1tm1Jabl mice, see Chapter 2 (Mague et al., 2009).
Briefly, we used site-directed mutagenesis in a bacterial artificial chromosome containing
the C57BL/6 mouse oprm1 to eliminate an equivalent N-linked glycosylation site to the
A118G SNP found in humans by replacing the adenine at nucleotide position 112 with a
guanine, resulting in an aspartic acid substitution of asparagine at amino acid position
38]. These mice were maintained on a C57BL/6 background and were bred, group
housed, and maintained on a 12 h light/dark cycle with food and water available ad
libitum in accordance with the University of Pennsylvania Animal Care and Use
Committee.

Voltage-sensitive dye imaging (VSDi). VSDi experiments were performed according to
previous studies [(Ang et al., 2005, 2006); for detailed methodology, see (Carlson and
Coulter, 2008)]. Briefly, mice were decapitated following isoflurane anesthesia. The
brain was removed and horizontal hippocampal slices (350 #m) were cut using an
Integraslice 7550 PSDS vibrating microtome (Campden Instruments, Lafayette, IN) in
ice-cold sucrose artificial cerebrospinal fluid (ACSF), in which NaCl was replaced with
an equiosmolar concentration of sucrose. ACSF consisted of 130 NaCl, 3 mM KCl, 1.25
mM NaH2PO4, 26 mM NaHCO3, 10 mM glucose, 1 mM MgCl2, 2 mM CaCl2 (pH 7.27.4 when saturated with 95% O2/5% CO2). Slices were then transferred to a static
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interface chamber (34°C) for 30 min and kept at 22-25°C thereafter. The osmolarity of all
solutions was 305-315 mOsm.
Slices were stained for 20 min with 0.125 mg/ml (in ACSF) of the voltage
sensitive dye di-3-ANEPPDHQ (D36801, Invitogen), and imaged in an oxygenated
interface chamber using an 80 x 80 CCD camera recording at a 1 kHz frame rate
(NeuroCCD: RedShirtImaging, Decatur, GA). Epi-illumination was provided by a
custom LED illuminator. Compared to the more commonly used photodiode array, the
CCD chip well size (215,000 electrons) requires use of relatively low light-intensities,
thereby minimizing photodynamic damage. Schaffer collateral stimulation using a single
20-µA, 200-µs pulse was administered with the electrode placed in SR near the
CA3/CA1 border (Figure 1a,b). This stimulation paradigm was utilized to highlight
influences of PV interneurons, as these cells have been shown to respond with high
reliability to initial, but not repeated, afferent input (Pouille and Scanziani, 2004;
Spruston, 2008). A field-recording electrode was also placed in SR to monitor population
responses following stimulation; these data, however, were not analyzed or included in
this manuscript. After initial electrode-placement and evaluation of population responses,
the slice was allowed to recover for at least 5 min prior to testing. Baseline responses
elicited by 12 single-stimulus trials, each separated by 20 s, were recorded during bath
application of ACSF. Following these recordings, the control ACSF was replaced by
ACSF containing the selective MOPR agonist [d-Ala(2),N-Me-Phe(4),Gly(5)-ol]enkephalin [DAMGO; 1 µM (Sigma-Aldrich)], which bathed the slice for at least 10 min
prior to the presentation of 12 single-stimulus trials of 20-µA, 200-µs pulses.
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Data analyses. VSD data was analyzed in IGOR (Wavemetrics, Lake Oswego, OR) on
12-trial-averages as previously described (Ang et al., 2005, 2006). Briefly, fluorescencechanges were calculated as the percent change in fluorescence divided by the resting
fluorescence (%&F/F0). Fitted double exponentials were subtracted from the normalized
fluorescence to compensate for photobleaching. ROI Quantification: Local VSD signals
were quantified from visually-identified regions of interest (ROIs), including SR and SO
(Figure 1b,c). To evaluate the extent of spatial activation, we measured the active area in
each ROI by determining the percentage of pixels that exhibited depolarization
corresponding to responses greater than 3 standard deviations above noise levels
following stimulation. Next, using two-dimensional (2D) traces showing changes in
fluorescence over time averaged between all pixels within each ROI (Figure 1d), we
determined the peak amplitude of the excitatory response corresponding to the greatest
positive change in fluorescence. Lastly, we identified the tau, which describes the
duration of the excitatory event, by calculating the time to return to baseline from peak
excitation using nonlinear regression analyses in IGOR (Figure 1d). Raster Plot
Quantification: Raster plots were generated by drawing a line through the peak of the
response from SO to the SLM over the slice image and plotting the fluorescence signal
from those pixels that fall under the line for all sampling points in time (Figure 1e). The
peak amplitude and tau were calculated from 2D traces drawn for average pixel-changes
corresponding to SO, SR, and SLM (Figure 2bi).
To determine net excitatory changes resulting from DAMGO administration, we
employed two methods of analysis: a baseline-normalized method that compared the
values obtained above before and after drug application and a raster plot subtraction
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method that compared pixel-changes prior to quantification. For the first method, we
normalized the DAMGO-mediated response with respect to each animal’s baseline
response for each of the parameters (e.g., area, amplitude, and tau) in the SR and SO for
both ROI and raster plot quantifications [(DAMGO – Baseline)/Baseline $ 100]. The
second method involved subtracting the DAMGO raster plot (Figure 2aii) from the basal
raster plot (Figure 2ai), resulting in a representation of the alteration in inhibitory
regulation as a result of MOPR stimulation (Figure 2aiii). From 2D traces corresponding
to average subtracted pixel-changes for SO, SR, and SLM, we determined 1) the peak
amplitude of disinhibition, determined by the greatest change in fluorescence (%&F/F0),
2) the duration of disinhibition, measured as time (ms) that the loss of inhibition
remained elevated, and 3) the area under the curve (AUC), which summed the subtracted
changes in fluorescence for a 50-ms window following the stimulation (Figure 2biii).
Statistical analyses were performed with GraphPad Prism 5.0 software package
(GraphPad Software, San Diego, CA). Differences between groups (genotype and sex)
were assessed using two-way ANOVAs.
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RESULTS
Quantification of baseline responses
To evaluate differences in circuit responses to afferent activity, compound
population responses in CA1 were induced with a single 20-#A, 200-#s pulse delivered
to Schaffer collateral axons passing through SR of CA1. VSDi of area CA1 recorded an
evoked fast depolarization followed by a rapid repolarization (Figure 1c–e), reflecting
responses at the single-cell level (Ang et al., 2005, 2006; Carlson and Coulter, 2008). As
previously validated, these alterations in fluorescence depict net functional changes in
neuronal activity, which have been shown to be comparable to AMPA/NMDA-mediated
EPSPs and GABA-mediated IPSPs measured by intracellular electrophysiologal
techniques (Ang et al., 2005, 2006; Carlson and Coulter, 2008). The initial
depolarization, which directly activated CA1 dendrites and local interneurons, propagated
to distal regions of SR and outwards towards SLM and SO and was followed by a longer
hyperpolarization. This can be visualized spatially in snapshots of the averaged peak
excitatory (Figure 1ci) or inhibitory (Figure 1cii) responses and temporally as 2D traces of
fluorescence changes over time (Figure 1d) or raster plots of activity, which show
changes in fluorescence across space and time (Figure 1e).
We employed several methods of analysis in an effort to evaluate different aspects
of circuitry responses that may be altered as a result of the MOPR SNP. To examine
average pixel-changes within ROIs, we measured the area, amplitude, and tau (duration)
of the response. Raster plots depict the fluorescence-change over time of pixels imaged
along a line drawn through the peak area of activation/inhibition of the SO, SR, and
SLM. We analyzed the amplitude and the duration of the responses for these raster plots
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to more directly assess the peak responses, as these data exclude areas within ROIs that
did not change as a result of the stimulation. Though this method precludes examination
of the area of activation, it does provide a uniform method for determining response
amplitudes and kinetics.
A112 and G112 animals, both male and female, displayed similar VSDi responses
to Schaffer collateral stimulation under basal conditions. In the SR (Figure 3), there was a
trend toward a decrease in basal responses in the G112 animals when measuring the peak
amplitude of the ROI (Figure 3b) and a significant decrease in G112 animals when
evaluating the peak amplitude of the raster plot (main effect of genotype, F1,19 = 5.26, p <
0.05; Figure 3e). Similar to the SR, there were trends in the SO that were not significantly
different (Figure 4). For instance, the females of both genotypes had slightly lower
baseline areas of activation (Figure 3a) and peak amplitudes for both ROI (Figure 3b) and
raster plot (Figure 3e) quantifications. All other attributes were virtually identical
between groups. Taken together, despite the presence of some minor trends, the baseline
responses were similar for all groups, suggesting that the A112G SNP did not
substantially alter basal circuit function of the hippocampus.

Analysis of DAMGO-mediated response-changes
In order to determine if the A112G SNP alters hippocampal circuit activity during
MOPR stimulation, we first examined responses following application of the highly
specific MOPR agonist DAMGO (1 µM) and normalized these to each animal’s basal
response. In accordance with previous studies (McQuiston and Saggau, 2003;
McQuiston, 2007) and expectations for agents that inhibit GABAergic release, we found
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increases in neuronal activation following DAMGO administration in wild-type mice
(Figure 2). In contrast, this effect was greatly reduced in G/G mice, suggesting a loss of
receptor function resulting from this SNP.
Specifically, in the SR there was a significant reduction in the ability of DAMGO
to prolong the excitatory event in G/G animals (Figure 4). The tau increased by ~40%
following DAMGO application in wild-type mice, but was unaffected in the G/G
animals, both for the ROI (main effect of genotype, F1,19 = 9.167, p < 0.01; Figure 5c)
and raster plot quantifications (main effect of genotype, F1,19 = 18.92, p < 0.001; Figure
5f). There were no significant alterations in the amplitude or the area of activation,
suggesting a dissociation between the initial peak response and the kinetics. In the SO,
there was a trend towards a selective decrease in G112 females for most of the
parameters measured, though these differences were not significant (Figure 6).
A problem with normalizing the DAMGO responses to the baseline responses is
that in the event that an animal displayed low or an absence of a baseline response, the
normalized result was either exponentially high or undefined, respectively, as a result of
dividing by this low or zero value corresponding to the baseline response. For a few
animals, in which the baseline response in the SO was small, we were unable to include
the normalized data as they were orders of magnitude higher than the average. There
were also a few animals, in which the baseline response in the SO was negligible, that a
value was unable to be ascertained; this could, in part, explain why trends in SO were not
significant. As such, we sought to find a method of analysis that could compare baseline
and DAMGO-mediated responses before determining values. To that end, we subtracted
the raster plot pixel-changes following DAMGO application from the raster plot
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responses observed under basal conditions in order to highlight the loss of inhibition due
to MOPR-stimulated GABA inactivation. Since MOPR stimulation with DAMGO
effectively decreases GABA transmission, any increase in excitatory events must have
occurred due to this reduction in inhibitory modulation: the subtracted raster plots
illustrate this MOPR-mediated loss of inhibition. An advantage of this novel approach is
that it allowed us to more reliably compare drug treatment effects across genotypes and
sexes. By subtracting the actual pixel responses between sessions, we eliminated the
requirement for excessive numerical transformations and were able to analyze 2D traces
quantified directly from the subtracted plot.
Comparing the subtracted raster plots between genotypes and sexes showed that
while all groups showed an initial decrease in inhibitory modulation following DAMGO
application, the wild-type animals had an elevated and prolonged response compared to
the G/G mice (Figure 7a). Indeed, these observations were supported by quantification of
raster plots for each of the regions within CA1. In order to identify differences between
groups, we used a 2D trace of the subtracted pixel-changes over time for each region of
CA1 and measured the peak amplitude and duration of the response in addition to the
area under the curve (AUC) (Figure 7b). In the SO, there were significant reductions in
the ability of DAMGO to disinhibit excitatory responses both in G/G animals and in
females, without an interaction between these effects. The G/G genotype and the females
showed reduced disinhibition compared to their respective counterparts for the peak
amplitude (main effects of genotype, F1,19 = 7.45, p < 0.05 and sex, F1,19 = 6.30, p < 0.05;
Figure 7bi), duration (main effects of genotype, F1,19 = 22.58, p < 0.001 and sex, F1,19 =
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6.05, p < 0.05; Figure 7bii), and the AUC (main effects of genotype, F1,19 = 20.68, p <
0.001 and sex, F1,19 = 9.94, p < 0.01; Figure 7biii).
We found a similar pattern in the SR, in which there was a significant reduction in
the ability of DAMGO to disinhibit excitatory responses in G/G animals, as demonstrated
by decreases in the peak amplitude (main effect of genotype, F1,19 = 13.76, p < 0.01;
Figure 7biv), duration (main effect of genotype, F1,19 = 47.12, p < 0.0001; Figure 7bv),
and the AUC (main effect of genotype, F1,19 = 22.37, p < 0.001; Figure 7bvi). There was
also a main effect of sex for the duration of response, in which the females of both
genotypes showed reduced disinhibition compared to their male counterparts (main effect
of sex, F1,19 = 10.67, p < 0.01; Figure 7bv); there was not, however, an interaction
between genotype and sex main effects. Another advantage of this analysis was that it
allowed us to evaluate differences in SLM, a region that, due to its lower basal responses,
we could not otherwise have analyzed. Though the responses for all groups were lower in
this region compared to the SR and SO, there was still a significantly reduced
disinhibition in the SLM for the G/G animals for the peak (main effect of genotype, F1,19
= 6.30, p < 0.05; Figure 7bvii), duration (main effect of genotype, F1,19 = 8.42, p < 0.05;
Figure 7bviii), and AUC (main effect of genotype, F1,19 = 18.76, p < 0.001; Figure 7bix).
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DISCUSSION
MOPR stimulation in the hippocampus increases net excitatory activity by
decreasing GABAergic inhibition from local interneurons, which likely results in
disruption of pyramidal cell firing synchrony and an alteration in hippocampal function
(Faulkner et al., 1998). A common SNP in the gene encoding the MOPR has been shown
to alter a variety of behaviors and drug responses in clinical populations (for review, see
Chapter 1; Mague and Blendy, 2010) and in animal models (Barr and Goldman, 2006;
Mague et al., 2009; Ramchandani et al., 2010). Neither the extent of these changes nor
the mechanisms mediating the effects are completely understood. We used VSDi
techniques to investigate circuit changes in the hippocampus, a region that showed
similar MOPR expression levels between genotypes and sexes in A112G mice, in order
to determine if functional alterations resulting from this SNP could better inform results
from previous clinical and preclinical studies. Additionally, we developed a novel
method of VSDi analysis to highlight the disinhibitory actions of MOPR activation.
Overall, we found that the augmentation of excitatory responses elicited by DAMGO
administration in wild-type animals was reduced in animals homozygous for the G112
allele. This reduction was particularly striking in raster plot subtraction analyses in which
DAMGO-mediated responses of individual pixels were subtracted from basal responses,
revealing the loss of inhibition caused by the MOPR activation.
Previous work using similar methodology has evaluated GABAergic mediation of
MOPR-stimulated response-augmentations in hippocampal slices (McQuiston and
Saggau, 2003; McQuiston, 2007). In these studies, DAMGO application increased
neuronal activation throughout the CA1 regardless of the specific area stimulated (e.g.,
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SR, SO, SLM). These responses were mediated by either GABAA (McQuiston and
Saggau, 2003) or GABAB (McQuiston, 2007) receptors, depending on the duration of the
simulation paradigm utilized. In the present studies, the normalized data showed
moderate increases in the SR and more substantial elevations occurring in the SO. This
could be due to ceiling effects in the SR: since stimulation of the SR caused a greater
basal activity in this region compared to SO, it is not surprising that there were greater
increases in the SO when comparing as percentages of baseline responses. Indeed, in
previous studies, the augmentation of responses was lower in the SR compared to SO
when stimulation was directed to the SR (McQuiston and Saggau, 2003). Raster plot
subtraction analyses, however, showed that dendritic disinhibition was equivalent
between the SO and SR, but less robust in the SLM. The disparity between the DAMGO
normalization and raster plot subtraction methods highlights the limitations of the former
method of analysis. Larger basal responses may lower the potential for augmentation by
DAMGO administration. Likewise, smaller basal responses might allow for greater
augmentation; however, this could also increase variability within groups or result in the
exclusion of values that are exponentially high or undefined. By quantifying the results
only after evaluating drug-mediated alterations in pixel-changes via this novel raster plot
subtraction method, we were able to eliminate these outcomes and produce more uniform
results.
Baseline responses were similar between genotypes and sexes. However, there
was a significantly lower peak response in the SR in the G/G animals. This could result
from enhanced tonic GABAergic activity, possibly suggesting either a reduction in
efficacy of endogenous MOPR modulation of GABA activity or, alternatively, a
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reduction in endogenous opioidergic tone in G/G animals. However, this effect was not
seen for other measures of responses in the SR or SO, suggesting only a subtle
consequence of these potential baseline alterations. Previous work with these mice did
not uncover any robust baseline differences, but only reductions in morphine-mediated
behaviors. One experiment, however, showed that non-morphine-dependent female G/G
mice responded aversively to acute naloxone administration, which might suggest an
increased endogenous opioidergic tone in G/G female mice (see Chapter 2; Mague et al.,
2009). However, further studies are needed to evaluate the endogenous tone of opioid
peptides in this mouse model.
Despite similar basal responses, there was a pronounced difference between
genotypes following application of DAMGO. Normalization of ROI and raster plot
results revealed similar increases in the area of activation and peak responses between
genotypes and sexes, but a significant reduction in the duration of the response for G/G
animals in the SR. The raster plot subtraction analysis, however, revealed more robust
MOPR deficits in the G/G animals in all CA1 regions tested. Though both genotypes
show an initial peak disinhibitory effect of DAMGO, this response was more intense and
prolonged in A/A animals. This resembles previous studies in which G/G animals
responded to the locomotor-activating and antinociceptive properties of acute morphine
administration, albeit at levels greatly reduced compared to A/A mice. Since the extent
and duration of responses seems to be most affected, these data suggest that there could
be alterations in the desensitization or trafficking of the receptor; these effects have not
been evaluated in these mice.
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In the current experiment, we also found significant reductions in the female
responses to MOPR activation compared to males, regardless of genotype. This was not
surprising given the frequency of reported sex-differences in response to opioid
administration (Craft, 2008). Opioids have been shown to be more efficacious in males
compared to females in both rodent (Kepler et al., 1989) and human (Cepeda and Carr,
2003) studies investigating sex-differences in the analgesic properties of opioids. In
contrast, female rats respond more robustly to the rewarding properties of opioids (Cicero
et al., 2003) and it has been shown that women are more likely to abuse prescription
opioid analgesics (Roe et al., 2002). Specifically in the hippocampus, ovarian steroid
hormones have been shown to influence levels of opioid peptides (Roman et al., 2006;
Williams et al., 2011) and the availability of MOPRs on the surface of PV cells (TorresReveron et al., 2009). In contrast to our previous studies, however, we did not
demonstrate interactions between genotype and sex. This could suggest that differences
in CA1 responses to MOPR activation may not underlie the sex-specific reduction in
morphine-conditioned place-preference studies. Alternatively, these behaviors may be
linked by shared U-shaped dose-responses in these experiments. Though there was not an
interaction between genotype and sex, there were similarities in the patterns of response
for both VSDi and place-conditioning studies. In the present studies, there was a
reduction in response to DAMGO for both G/G mice and female mice compared to their
respective A/A or male counterparts. As a result, the female A/A and the male G/G mice
displayed similar MOPR-activated responses, while the male A/A mice responded more
robustly than all other groups and the female G/G hardly responded at all. Likewise,
female A/A and male G/G mice displayed similarly strong preferences for morphine93

paired environments, whereas male A/A mice showed slightly lower preferences and the
G/G female mice did not demonstrate morphine reward at all (see Chapter 2, Figure 4).
Other studies have demonstrated inverted U-shaped dose-responses to the acute
locomotor activating effects of morphine (Bardo et al., 1997). Since CA1 MOPRmediated GABAergic modulation has been shown to be necessary for the expression of
morphine CPP (Rezayof et al., 2007), it is possible that in our CPP studies the dose tested
provided the optimal CA1 responses in the female A/A and male G/G mice, resulting in
maximal morphine reward. A complete dose-response experiment might help elucidate
this hypothesis.
Since VSDi responses show net activity of entire circuits, we were unable to
isolate responses of specific subpopulations of interneurons and, thus, cannot
unequivocally ascribe our findings to MOPR modulation of PV basket cells. However,
previous studies have shown that MOPRs are found predominantly on these interneurons
(Drake and Milner, 1999, 2002) and that stimulation of these cells disinhibits
glutamatergic dendrites (Glickfeld et al., 2008). This is supported by the findings
provided by the stimulation paradigm utilized in these studies, in which a single 200-µs
pulse was administered, as the PV interneurons have been shown to respond with high
reliability to initial, but not repeated, afferent input (Pouille and Scanziani, 2004;
Spruston, 2008). Also, GABAA receptors located opposite PV cell terminals produce
IPSPs that rise and decay very rapidly (Lavoie et al., 1997; Klausberger et al., 2002).
Indeed, other studies evaluating MOPR-mediated elevations of CA1 responses to Shaffer
collateral stimulation found that paired current pulses, similar to the single pulses utilized
in the present studies, were mediated by GABAA receptors (McQuiston and Saggau,
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2003), while DAMGO-induced augmentations of CA1 responses following prolonged
stimulation were mediated by GABAB receptors (McQuiston, 2007). These features of
PV-containing, fast-spiking interneurons enable them to induce a reliable and brief, yet
intense, somatic shunting of postsynaptic conductance (Vida et al., 2006; Bartos et al.,
2007). Thus, reduced PV interneuron inhibition is a plausible explanation for the
augmentation of CA1 responses following DAMGO administration in these current
experiments. In addition, the reduced disinhibition demonstrated by the G/G animals
following DAMGO administration suggests a disruption in MOPR modulation of these
PV interneurons resulting from the A112G SNP.
A consequence of the increase in excitatory responses, demonstrated in wild-type
mice, could be a reduction in both neuronal synchrony and the formation of highfrequency oscillatory activity. Indeed, PV interneurons have been shown to be important
in generating gamma-band oscillations in the hippocampus (Bartos et al., 2007; Fuchs et
al., 2007). Given the reduced DAMGO-mediated augmentation of responses in the G/G
animals, we would predict that reductions in gamma-activity resulting from MOPR
activation (Sun et al., 2006; Zuo et al., 2007) would be inhibited in these animals. Future
studies investigating EEG activity in CA1 following morphine administration will
address these predictions.
The reduced effect of DAMGO in G/G animals further supports a loss of function
of the MOPR as a consequence of this SNP. Previous work with this mouse line has
provided evidence for reduced MOPR expression and decreased behavioral responses to
acute morphine administration; likewise, clinical findings have demonstrated a reduced
response to the analgesic properties of opioids (Chou et al., 2006b; Sia et al., 2008). In
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support of these findings, authors often cite in vitro studies showing decreases in MOPR
expression (Befort et al., 2001; Zhang et al., 2005). However, the data presented here
suggest that receptor function may be disrupted irrespective of alterations in expression.
The hippocampus was chosen, in part, due to the lack of differences in expression
between genotypes and sexes. The reduction in DAMGO-mediated responses suggests
that MOPR function is impaired in a region in which expression is similar. One caveat,
however, exists in the specificity of the circuit utilized for VSDi studies. While responses
to DAMGO application were tested only in CA1 of the hippocampus in slices taken from
the middle of the structure (i.e., neither dorsal nor ventral), expression level changes (e.g.,
mRNA and protein) were evaluated for the region as a whole. It is possible that
expression-pattern differences between genotypes of sexes could explain our results,
(e.g., differences in CA1 MOPR expression may be obscured when evaluating the entire
structure). Future work using quantitative receptor autoradiography will determine more
specific patterns of MOPR expression.
In summary, we utilized VSDi in a hippocampal slice preparation in order to
evaluate circuit responses in a mouse model of the human A118G OPRM1 SNP. Our
experiments show that MOPR activation by DAMGO increases net excitatory responses
in A/A mice, an effect that was significantly reduced in G/G mice. Additionally, these
studies demonstrate that these deficits occur despite similar MOPR expression levels.
Future work will establish how the changes in circuit function may affect CA1 synchrony
and hippocampal function.
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FIGURE LEGENDS
Figure 1. VSDi procedure, quantification, and analysis (a) A diagram of hippocampus
circuitry illustrates the stimulus paradigm utilized in this study. A stimulating electrode
was placed in the Shaffer collateral axons from CA3 pyramidal cells and a recording
electrode was placed in the distal end of SR in CA1. The light gray line represents the
pyramidal cell layer and the dotted black line delineates the path of the Shaffer collateral
axons. The dark gray box depicts the area visualized in b and c. (b) Horizontal slices
containing the hippocampus were visualized under a 10x lens. The black triangles show
the stimulating electrode placement and the white triangle shows the placement of the
recording electrode. The structures and regions are labeled thusly: SO – stratum oriens,
SR – stratum radiatum, SLM – stratum lacunosum moleculare, CTX – cortex, DG –
dentate gyrus. (c) The average normalized pixel-changes for the duration indicated
following stimulation demonstrates the peak excitatory (ci) and inhibitory (cii) responses
for a representative wild-type animal. Changes in membrane voltage are illustrated in red
(excitation) or blue (inhibition). The dotted area indicates the ROI from which the area of
activation is determined and whose 2D trace is quantified in d. The black line
corresponds to the raster plot shown in e. (d) A 2D trace of the average pixel-changes
over time for all the pixels contained within the SR region outlined in c was used to
quantify the peak amplitude and tau. The scale of response amplitudes corresponds to the
numerical axis of the color scale drawn to the right. (e) A raster plot corresponding to the
pixels along the black line drawn in c shows the average pixel-changes over time for the
SO, SR, and SLM.
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Figure 3.1
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Figure 2. Raster plot quantification and subtraction analysis (a) Raster plots
corresponding to the pixels along the black line drawn in figure 1c show the average
pixel-changes over time for the SO, SR, and SLM during baseline (ai) or DAMGO
application (aii). Subtraction of the baseline plots from the DAMGO plots shows the net
disinhibition resulting from MOPR activation (aiii). Changes in membrane voltage are
illustrated in red (excitation) or blue (inhibition). (b) 2D traces of the average pixelchanges over time for all the pixels contained with the SR region of the raster plot were
used to quantify the amplitude and tau (bi, ii). A 2D trace of the SR region shows the
quantification of subtracted raster plots. The amplitude was determined by the peak
disinhibitory response. The duration, shown as the horizontal dashed red line, measured
the time (ms) during which disinhibition was elevated above noise. The area under the
curve (AUC; diagonal red lines) was calculated for a 50-ms window following
stimulation. For all 2D plots, the scales of response amplitudes correspond to the
numerical axis of the color scales drawn to the left of each trace.
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Figure 3.2
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Figure 3. Baseline responses in SR There were no differences between genotypes or
sexes for ROI-quantified basal responses in area of activation (a), amplitude (b), or tau
(c). For raster plot quantifications, there was a significant reduction in the peak excitation
for G/G mice (d) but not for the tau (e). All data are presented as mean ± SEM, n = 5; * p
< 0.05 compared to A/A.
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Figure 3.3
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Figure 4. Baseline responses in SO There were no differences between genotypes or
sexes for ROI-quantified basal responses in area of activation (a), amplitude (b), or tau
(c) nor were there differences for raster plot quantifications of amplitude (d) or tau (e).
All data are presented as mean ± SEM, n = 4–5.
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Figure 3.4
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Figure 5. Normalized DAMGO-mediated responses in SR For ROI-quantified results,
there were no gentoype or sex differences in the ability of DAMGO to affect the area of
activation (a) or amplitude (b). DAMGO-mediated elongations of response duration were
reduced in G/G mice (c). For raster plot quantifications, there was not an alteration in
amplitude responses to DAMGO application (d). DAMGO-mediated elongations of
response duration were reduced in G/G mice (e). All data are presented as mean ± SEM,
n = 5; ** p < 0.01, *** p < 0.001 compared to A/A.
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Figure 3.5
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Figure 6. Normalized DAMGO-mediated responses in SO For ROI-quantified results,
there were no gentoype or sex differences in the ability of DAMGO to affect the area of
activation (a) or amplitude (b) or tau (c). For raster plot quantifications, there were no
alterations the ability of DAMGO to affect the amplitude (d) or tau (e). All data are
presented as mean ± SEM, n = 3–5.
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Figure 3.6
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Figure 7. Raster plot subtraction analyses for SO, SR and SLM (a) Representative
subtracted raster plots for A/A male (ai), A/A female (aii), G/G male (aiii), and G/G
female (aiv) show the loss of inhibition resulting from DAMGO administration. (b)
Analysis of 2D traces from each strata of CA1 reveals alterations in genotype or sex
responses to DAMGO administration. In the SO, both the G/G animals and females, each
compared to their respective counterparts, showed decreases in the amplitude (bi),
duration (bii) and AUC (biii). In the SR, G/G animals showed reductions in amplitude
(biv), duration (bv), and AUC (bvi); additionally, there was a significant reduction in
females compared to males for duration only (bv). In the SLM, levels of disinhibition
were lower compared to the other CA1 regions; however, G/G animals still showed a
decreased response to DAMGO administration measured by the amplitude (bvii), duration
(bviii), and AUC (bix). All data are presented as mean ± SEM, n = 5; * p < 0.05, ** p <
0.01, *** p < 0.001, † p < 0.0001 compared to A/A; + p < 0.05 compared to males.
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Figure 3.7
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CHAPTER 4: CONCLUSIONS AND FUTURE
DIRECTIONS

The previous chapters describe my work characterizing a novel mouse model of a
common human variation in the gene encoding the µ-opioid receptor. Through detailing
alterations in receptor expression and function using this model, I have helped extend our
understanding of the functional consequences of this SNP. A myriad of clinical studies
have found associations of the A118G SNP with several drug and behavioral responses;
however, limitations in our abilities to directly study receptor function or determine
causative outcomes in human populations precludes uncovering the mechanisms
mediating these changes. Conversely, in vitro studies, well-equipped to establish
molecular adaptations resulting from this SNP, are often performed in heterologous
cellular systems, rendering functional implications difficult to interpret. As such, we
generated a mouse containing an equivalent SNP in order to evaluate both the changes in
receptor expression/function and the behavioral consequences that result from these
alterations.
Our initial work, detailed in Chapter 2, determined that there is a reduction in
MOPR expression and a deficit in several morphine-evoked responses in mice possessing
the G118 allele compared to their wild-type counterparts. Interestingly, we demonstrated
a sex-specific reduction in the rewarding properties of morphine administration and the
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dysphoria associated with morphine withdrawal in female G112 allele-carriers; all other
differences between genotypes were present in both males and females. I continued this
research, described in Chapter 3, by examining how changes in receptor function might
integrate and alter circuit activity by analyzing hippocampal responses using voltagesensitive dye imaging techniques. Similar to my original findings, I demonstrated deficits
in receptor function in G/G animals. DAMGO application disinhibited cells in wild-type
animals, and effect that was significantly reduced in male and female G112 mice. These
results, together with clinical and in vitro findings from other labs, validate this mouse
model of the A118G SNP and justify continued work to determine the mechanisms
underlying the changes seen in human populations.
The use of mouse models allows for an important, bidirectional evaluation of
genetic contributions to human illness and drug response: observations of human traits
can direct investigation in mice and, inversely, new discoveries in the mouse can target
new traits for study in humans. Firstly, using the mouse model to study known human
phenotypes can help us understand the mechanisms underlying these changes, which can
be utilized to either circumvent problems in the human carriers or mimic the putative
advantages. For instance, individuals with at least one copy of the G118 allele respond
poorly to the analgesic properties of opioids and, consequently, endure more discomfort
following surgical procedures (Chou et al., 2006a; Sia et al., 2008). Thorough evaluation
of opioidergic- and non-opioidergic-mediated reductions in pain responses in the animal
model might identify compounds that are more therapeutically efficacious for those with
the G118 allele. Additionally, it has been shown that G118 allele-carriers respond more
effectively to treatments for alcohol (Crowley et al., 2003) and nicotine (Lerman et al.,
112

2004) cessation. Investigation into the mechanisms mediating these outcomes could
generate improved treatment options for those carriers of the A118 allele who do not
benefit from the putative advantages conferred by the SNP. Indeed, another group has
generated a mouse model of the same A118G SNP and identified responses to alcohol
that may help explain differences conferred by the SNP (Ramchandani et al., 2010).
Secondly, analysis of the mouse model may identify new phenotypes that have
not been recognized in clinical studies. For example, our results have shown multiple
occurrences of sex-specific reductions in function due to the SNP. As many clinical
studies are underpowered for the identification of sex-differences, significant effects may
be obscured. Our results highlight the importance of evaluating sex-differences when
investigating this SNP. Additionally, I have shown several other features of this SNP that
do not directly correspond to any known clinical effects. For instance, G112 mice showed
a reduction in the locomotor-activating effects of morphine and did not sensitize to
repeated administration. Sensitization has been associated with drug “wanting” and is
considered a cause for addicted behavior (Robinson and Berridge, 1993). Consequently,
the G118 should be associated with a decreased risk for developing opioid addiction.
Though this has been reported (Schinka et al., 2002), there are other studies that suggest
that the G118 allele is actually a risk for the disease (Zhang et al., 2006a), while others
found no influence of this SNP on this behavior (Gelernter et al., 1999; Franke et al.,
2001). As drug addiction is a complex disorder involving many genes, transmitter
systems, brain regions, and behaviors, it is difficult to assign vulnerability based on this
one SNP. However, it is perhaps more feasible to identify aspects of the disorder that are
affected by allele-differences. For instance, it is possible that populations of addicted
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patients could be distinguished by certain reasons for or responses to drug taking. In our
studies, though male G118 mice failed to sensitize to repeated morphine, they did
develop preferences for environments previously paired with morphine, showing they
still respond to the rewarding properties of the drug. Future clinical studies may find
parallel responses in humans.
Since this SNP has been associated with a variety of clinical responses, the
purpose for generating this mouse model was to address these many effects. As this
mouse has a specific mutation in the MOPR, I wanted to first report µ-opioid-specific
alterations, related to receptor changes and morphine responses, before encompassing
other drugs or transmitter systems. A large portion of the clinical literature is concerned
with direct, exogenous application of opioid ligands as they appertain to the maintenance
of pain and the development of drug dependence. However, a prevailing hypothesis
explaining the rewarding properties for alcohol and nicotine is that they stimulate the
release of endogenous opioids (Gianoulakis and Barcomb, 1987; Davenport et al., 1990),
which might explain why alterations in receptor function resulting from the SNP might
affect responses to these drugs. As such, it is important to next evaluate potential
differences in endogenous opioidergic modulation. Though a few of my results suggest
that there could be altered tonic MOPR activity, we have yet to specifically evaluate
basal or drug-evoked levels of #-endorphin in these mice. This would also provide insight
into how the stress system is affected by the SNP, as #-endorphin is released in response
to stress and provides negative feedback to stress circuitry. Studies have reported a
differential response to psychological versus pharmacological stressors: G118 allelecarriers had lower CORT responses while giving a public speech, but an increased CORT
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response to naloxone (Chong et al., 2006), suggesting a dysregulation of tonic #endorphin transmission. Future studies with these mice could evaluate the response to
physical, pharmacological, or behavioral stress.
Initially, I described reductions in responses to morphine-evoked behaviors,
which seemed to coincide with decreases in receptor expression. However, further
investigation uncovered functional differences in MOPR responses in the hippocampus, a
region that did not demonstrate expression-level changes, suggesting that these
alterations are mediated by something other than reductions in receptor number. Though
there were not differences in MOPR binding affinity, we have yet to investigate
alterations in downstream signaling or receptor trafficking, as these would greatly affect
receptor function and availability. Future work would identify how these processes may
contribute to changes conferred by this SNP.
It has been contested whether the A118G SNP confers a gain or loss of function.
Clinical studies that report elevations in biochemical or behavioral traits typically
describe elevations in #-endorphin binding (Bond et al., 1998) as the putative
mechanism. Alternatively, studies reporting deficits in behavior typically refer to
decreases in MOPR expression (Zhang et al., 2005) to explain the effects. While the
current experiments did not confirm increases in binding affinity or signal transduction,
they did corroborate decreases in MOPR expression. However, I have also shown that the
functional and behavioral consequences of the SNP do not seem to follow patterns
predicted by these changes in receptor number. This suggests that a more complex
interaction between receptor number, availability, and function must be occurring. Future
work with this model should help us to better understand the ways in which this SNP
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affects receptor function and, consequently, the alterations in behavior seen in the human
population.
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